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Abstract 
Viruses in the Bunyaviridae family cause disease in humans ranging from a mild transient fever 
to viral haemorrhagic fever. The orthobunyavirus genus is the largest within the family and 
contains the La Crosse virus (LACV). LACV is endemic in the USA, causing 85 % of 
neuroinvasive viral disease in children under the age of 15. The main pathogenicity factor of 
LACV is the NSs protein, an inhibitor of the type I interferon (IFN) induction. Previous work in 
our group identified the mechanism of LACV NSs inhibition. During infection, the NSs protein 
of LACV induces the proteasomal degradation of the largest subunit, RPB1, in transcription 
elongating RNA polymerase II. As a possible host cell interactor of LACV NSs that could 
mediate the degradation of RPB1, was Elongin C identified. Elongin C has been described to 
have two main functions in the cell: 1) as a subunit of the Elongin complex that increases RNA 
polymerase II transcription elongation rates, and 2) as a subunit of several cellular and viral 
ubiquitin E3 ligases. 
Here, I demonstrate that LACV NSs specifically sequesters Elongin C from the nucleoli, but 
does not change the sub-cellular localization of the other two subunits of the Elongin complex, 
Elongin A and B. The LACV NSs re-localization of Elongin C from the nucleoli had minimal 
effects on the nucleolar structure or the localization of a major nucleolar protein, Nucleolin. The 
re-localization of Elongin C by LACV NSs could be prevented by inhibiting the main protein 
export factor of the nucleus, CRM1, but the same inhibition did not rescue RPB1 from 
degradation. However, siRNA mediated knockdown of Elongin C partially rescued RPB1 from 
degradation concomitantly with a partially rescued of type I IFN induction. In attempts to map 
the functional domains of LACV NSs, I was able to dissect the inhibition of general host cell 
transcription and type I IFN induction. All LACV NSs mutants, generated at conserved sites in 
the NSs protein throughout the orthobunyavirus genus, had lost the ability to inhibit type I IFN 
induction while they all retained the inhibition of general transcription. However, two of the 
mutants did not show robust phenotypes, requiring further studies to clarify their respective 
roles. For the rest of the mutants, the inhibition of general transcription correlated with RPB1 
degradation, while the loss of type I IFN inhibition correlated partly with loss of Elongin C re-
localization and/or inhibition of transcriptionally active RPB1.  
Thus, I have established that the re-localization of Elongin C by LACV NSs might play a role in 
type I IFN inhibition. Furthermore, I was able to dissect the inhibition of general host 
transcription and type I IFN induction transcription, pointing towards two different mechanisms 
of inhibition. General transcription is inhibited by RPB1 degradation, while type I IFN 
inhibition correlates partly with RNA polymerase II elongation inhibition. 
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Zusammenfassung 
Viren der Familie Bunyaviridae verursachen Krankheiten beim Menschen die von einem 
leichten vorübergehendem Fieber bis hin zu viralem hämorrhagischen Fieber reichen. Die 
Orthobunyavirus Gattung ist die größte in der Familie und enthält das La Crosse Virus (LACV). 
LACV ist endemisch in den USA, wo es für 85% der neuroinvasiven Viruserkrankung bei 
Kindern unter dem Alter von 15 Jahren verantwortlich ist. Der Hauptpathogenitätsfaktor von 
LACV ist das NSs Protein, das die Typ I Interferon Antwort hemmt. Frühere Arbeiten in 
unserer Gruppe identifizierten den Mechanismus mit dem das LACV NSs die Hemmung 
vermittelt. Während der Infektion induziert das NSs Protein von LACV den proteasomalen 
Abbau der größten Untereinheit, RPB1, in der Transkriptions-elongierenden RNA-Polymerase 
II. Als möglicher Wirtszell-Interaktor von LACV NSs, das den Abbau von RPB1 vermitteln 
könnte, wurde Elongin C identifiziert. Für Elongin C wurden zwei Hauptfunktionen in der Zelle 
beschrieben: 1) als eine Untereinheit des Elongin Komplex, das die Transkriptions-
Elongationsrate der RNA-Polymerase II erhöht, und 2) als Untereinheit von mehreren zellulären 
und viralen Ubiquitin E3-Ligasen. 
Hier zeige ich, dass LACV NSs speziell Elongin C aus den Nukleoli sequestriert, aber nicht die 
subzelluläre Verteilung von den anderen beiden Untereinheiten, Elongin A und B, des Elongin 
Komplexes beeinflusst. Die LACV NSs-vermittelte Umverteilung von Elongin C aus den 
Nukleoli hat minimale Auswirkungen auf die Kernstruktur oder die Verteilung eines Haupt-
Nukleoli Proteins, Nukleolin. Die Umverteilung von Elongin C durch LACV NSs konnte durch 
Hemmung des Hauptproteinexportfaktors des Kerns, CRM1, verhindert werden aber nicht den 
Abbau von RPB1. siRNA-vermittelte Herunterregulation der Elongin C-Genexpression schützt 
RPB1 teilweise vor dem Abbau, begleitet von einer teilweise geretteten Typ I Interferon 
Antwort. In Versuchen die funktionellen Domänen von LACV NSs zu identifizieren, waren wir 
in der Lage die Hemmung der allgemeinen Transkription von der Transkriptionshemmung der 
Typ I Interferon Antwort zu trennen. Alle LACV NSs Mutanten, die an konservierten Stellen 
der ganzen Orthobunyavirus Gattung im NSs-Protein erzeugt wurden, haben die Fähigkeit 
verloren die Typ I Interferon Antwort zu hemmen, während sie die Hemmung der allgemeinen 
Transkription beibehalten haben. Zwei der Mutanten zeigten keinen robusten Phänotypen  und 
erfordern weitere Studien um ihre jeweiligen Rollen zu klären. Für den Rest der Mutanten 
korreliert die Hemmung der allgemeinen Transkription mit dem RPB1-Abbau, während der 
Verlust der Hemmung der Typ I Interferon Antwort teilweise mit dem Verlust der Elongin C 
Umverteilung und / oder Hemmung der transkriptionell-aktiven RPB1 korreliert. 
So haben wir festgestellt, dass die Umverteilung von Elongin C durch LACV NSs eine Rolle 
bei der Hemmung der Typ I Interferon Antwort spielen könnte. Darüber hinaus konnten wir die 
Hemmung der allgemeinen Wirtstranskription von der Transkriptionshemmung der Typ I 
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Interferon Antwort trennen, hinweisend auf zwei verschiedene Mechanismen der Hemmung. 
Die allgemeine Transkription wird durch den RPB1-Abbau gehemmt, während die Hemmung 
der Typ I Interferon Antwort teilweise mit der Hemmung der RNA-Polymerase II-Elongation 
korreliert.
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1. Introduction 
1.1. La Crosse Virus neuroinvasive disease 
The La Crosse virus (LACV) was isolated in May 1964, from autopsy samples taken from a 4-
year old girl who died in 1960 of meningoencephalitis in the town of La Crosse, Wisconsin. 
Based on serology the virus was demonstrated to belong to the California encephalitis group, in 
the orthobunyaviruses genus of the Bunyaviridae family of viruses [154]. LACV is endemic to 
the eastern USA, with a geographical distribution correlating with the main vector, the eastern 
tree-hole mosquito (Ochlerotatus triseriatus) [163]. However, LACV is currently spreading to 
un-affected areas of USA [60] possibly due to the introduction of the Asian tiger mosquito 
(Stegomyia albopicta) which can transmit the virus [55]. The eastern tree-hole mosquito has 
been demonstrated to maintain LACV in nature, via cyclic infection of chipmunks (Tamias 
striatus) or gray squirrels (Sciurus carolinensis), in which the virus reaches high enough titer to 
infect naïve blood sucking mosquitos [21, 53]. The LACV is released subcutaneously, upon 
infected mosquito feeding, and then replicates primarily in striated muscle cells, resulting in 
virus release into the blood stream. The mechanism how the virus reaches the brain is not 
known but two possibilities have been suggested; one study suggested that viral infection of the 
vascular endothelial cells in the brain releases virus into the central nervous system [21] while 
the other study suggested that the virus can reach the nasal turbinates and enters the CNS by this 
route [16]. 
Due to the vector transmission, LACV infections occur from July to September, with around 70 
cases/year of severe neuroinvasive infections in children under the age of 15, which accounts 
for 85% of viral neuroinvasive disease in this age group. In 0.5 – 2 % of the severe infections, 
the patient dies. However most LACV infections are either asymptomatic or under-diagnosed, 
with estimates of up to 300.000 infections/year in endemic areas [2, 52, 60]. Mild LACV 
infection causes general symptoms such as fever, headache and vomiting while in severe cases, 
most patients experienced seizures or disorientation. The diagnosis of LACV neuroinvasive 
infection, which manifests itself as encephalitis, meningitis or meningoencephalitis, is based on 
the clinical signs and serological tests for LACV specific IgM/IgG antibodies in serum and/or 
cerebrospinal fluid [95, 98, 154]. Long-lasting effects, in children who recovered from severe 
infection, have been demonstrated with decreased IQ scores, compared to age-matched groups, 
and an increased incidence of attention-deficit-hyperactivity disorder [95]. LACV infections 
have also been studied in relation to socioeconomic costs with estimates, for patients with 
severe infection, of up to 3.1 million $/patient [155]. There is no approved antiviral therapy 
against LACV, with severe cases being treated symptomatically. The broad-spectrum antiviral 
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ribavirin, to which LACV is sensitive in cell culture [35], was tested for treating severe LACV 
infections. However, no difference in infection resolution time or severity of the disease was 
observed, compared to placebo treatment, probably due to low concentration in the 
cerebrospinal fluid. Higher doses had severe side-effects and were therefore discontinued [96]. 
Several host factors have been implicated in the development of LACV neuroinvasive disease, 
in especially young individuals. The importance of innate immune activation by LACV 
infection, both in the periphery [151] and in the CNS [133], to limit the infection have been 
demonstrated. A reduced amount of myeloid dendritic cells in the periphery [151] and/or low 
levels of innate immune components in the developing brain of young individuals [133] have 
both been suggested to contribute in disease development in young individuals. A small study 
also demonstrated a possible involvement of certain HLA-types in disease incidence and 
severity [34]. However, the mechanism why young individuals develop severe disease is not 
clear. 
 
1.2. Bunyaviridae 
1.2.1. The Bunyaviridae family 
The Bunyaviridae family of viruses contain around 350 viruses divided in 5 genera: 
Orthobunyavirus, Nairovirus, Phlebovirus, Hantavirus and Tospovirus [3, 162]. All viruses are 
vector borne, e.g. transmitted by mosquitoes or ticks, except the hantaviruses, which are shed 
into the excrements and saliva of their persistently infected rodent hosts [57]. The prototype 
virus of the whole family is the Bunyamwera virus (BUNV), which belongs to the 
Orthobunyavirus genus. Examples of other viruses within each genus are: Crimean-Congo 
Hemorrhagic fever virus (Nairovirus), Rift Valley fever virus (RVFV) (Phlebovirus), Puumala 
virus (Hantavirus) and Tomato spotted wilt virus (Tospovirus) [57, 140]. The viruses in the 
family cause a wide range of disease in humans and animals (Orthobunyavirus, Nairovirus, 
Phlebovirus, Hantavirus) or plants (Tospovirus). In humans the diseases caused by viral 
infection range from febrile illness, to severe symptoms with hepatitis, encephalitis or 
haemorrhagic fever, while diseases in animals range from decrease milk production, to 
congenital malformation of foetuses and/or abortions [3, 57, 140, 162]. 
 
1.2.2. Bunyaviridae structure and genomic organization 
Bunyaviridae virions are circular pleomorphic in structure with a diameter of 75-115 nm [1]. 
The virions consist of a membranous bilayer [23] from which the receptor binding glycoproteins 
protrude [150]. The viral genome consists of 3 segments of negative-sense, single-stranded 
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RNA, where the name of each segment is based on its nucleotide length; small (S segment), 
medium (M segment) and large (L segment) [105] (Fig. 1B). For all genera in the family the 3 
segments encodes for a total of 4 structural proteins where the S segment encodes for the 
nucleoprotein (N), the M segment encodes for the two glycoproteins (GC) and (GN) and the L 
segment encoding for the RNA-dependent RNA-polymerase (L) [44, 51, 88, 104]. Viruses in 
the Orthobunyavirus, Phlebovirus and Tospovirus genera also express two non-structural 
proteins, the non-structural protein on the M segment (NSm) and the non-structural protein on 
the S segment (NSs) [51, 88] (Fig. 1B). Each segment has two untranslated regions, on either 
side of the open reading frame (ORF). The very 3’ and 5’ of each segment, in the respective 
untranslated region, are complementary in sequence. This complementarity allows for base 
pairing between the untranslated regions, forming a short stretch of double-stranded RNA called 
the “panhandle”, making the genomic content appear semi-circular in isolation [105]. The 
panhandle sequence is shared between viruses in the same genus, but not in-between 
Bunyaviridae genera [107, 120]. The viral RNA segment is coated by N proteins, forming 
ribonucleoprotein complexes that associates with viral polymerase L [106] (Fig. 1A). 
 
1.2.3. Bunyaviridae replication cycle 
Upon infection the surface glycoprotein GC binds to an unknown receptor on permissive cells, 
inducing a clathrin-dependent endocytosis [70, 112, 129]. Membrane fusion is induced by a 
decrease in endosomal pH, causing the GC protein to undergo a conformational change [113] 
exposing a fusion peptide, mapped to amino acid 1066 to 1087 for LACV GC [142]. LACV 
fusion have been determined to occur in the early endosome [70], while the related 
orthobunyavirus Oropouche virus fuses in the late endosome [129]. Upon fusion the 
ribonucleoprotein complexes are released into the cytoplasm [3]. Bunyaviridae transcription and 
replication occur in the cytoplasm [127]. The incoming L protein, present on the 
ribonucleoprotein complexes, performs primary transcription where viral mRNA is synthesised. 
During both viral transcription and replication, the panhandle is vital as a promoter [12]. 
Bunyaviridae mRNA transcription is dependent on cap-snatching, where the 5’ capped first ~15 
nucleotides are cleaved of from host cell mRNA and used as primers for viral transcription 
[108]. The LACV endonuclease domain, responsible for cap-snatching, is located in the N 
terminus of the L protein, which has high sequence similarity both within the orthobunyavirus 
genus and between genera [121]. Bunyaviridae mRNA lack a poly-A tail, where transcription of 
the LACV S segment was determined to end at a polyuridine tract, similarly to termination sites 
for other negative sense viruses [109]. Bunyaviridae transcription and replication, in 
mammalian cells, is dependent on ongoing translation [3, 14, 15, 119]. 
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Figure 1. Schematic representation of A) a Bunyaviridae virus particle and B) the coding 
strategy employed by orthobunyaviruses. The colours of the viral proteins in part A correspond 
to the colour of the respective ORF of the genome in part B. 
 
As the viral replication proceeds, both the genome and the antigenome, are encapsidated by the 
N protein. The Orthobunyavirus N proteins from LACV, BUNV, Schmallenberg virus (SBV) 
and Leanyer virus have all been determined to possess a positively charged cleft, 
accommodating 10-11 nucleotides/N protein, in-between two globular domains. Each globular 
domain of the N protein have a short arm responsible for multimerization, by extending over to 
the next N protein on a ribonucleoprotein complex [8, 91, 102, 122]. 
The M segment mRNA encodes for a polyprotein containing the glycoproteins GN and GC, and 
for some genera a non-structural protein (NSm) separating the two viral surface proteins [88], 
(Fig 1B). The polyprotein is translated at the ER and then cleaved into the three proteins by an 
unknown protease. Both glycoproteins are type I integral membrane proteins that heterodimers 
in the ER and are then transported to the Golgi compartment [134, 135]. The targeting sequence 
for both GN and GC to the Golgi compartment, where viral assembly occur, has been mapped to 
the trans-membrane domain of the GN protein [29, 134, 137]. Infection with Bunyaviridae 
viruses causes a large reorganization of the Golgi compartment. Tubular structures, between 
0.2-1 µm long with a terminal globular domain, protrude from the Golgi cisternae and contain 
the N, L and NSm proteins, as well as double stranded RNA, indicating that these structures are 
the replication site [45, 128]. The NSm protein is an integral membrane protein essential for 
viral viability, playing a role in virus assembly and in the formation of the tubular structures in 
Golgi [45, 136]. Assembled virions move through the Golgi compartment, during which a 
maturation process occurs [103, 128]. The virions are released from infected cells via transport 
through the exocytic pathway [138] requiring the participation of the actin cytoskeleton [3, 45, 
130]. 
 
L
S
M
L-segment
M-segment
S-segment
A B
UTR UTR3 5 RNA-dependent RNA-polymerase , L
UTR UTR3 5 GCNSmGN
UTR UTR3 5 N
NSs
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1.3. The Orthobunyavirus NSs protein 
Most viruses in the orthobunyavirus genus code for a non-structural protein on the S-segment 
(NSs). The NSs protein is translated from a +1 open reading frame embedded in the 
nucleoprotein mRNA [51] (Fig. 1B). Depending on its expression level, the BUNV NSs protein 
was observed to localize to the cytoplasm (low expression) or nucleus (high expression) [152, 
164]. Orthobunyavirus NSs proteins are hydrophobic proteins with a transient expression in the 
beginning of the infection. The degradation of Orthobunyavirus NSs proteins occur via the 
proteasome, as demonstrated for BUNV NSs [50, 157]. 
The main function of the NSs protein, during infection of mammalian cells, has thus far 
primarily been studied for BUNV, LACV and SBV [19, 26, 43, 158]. These studies where aided 
by the development of reverse genetic systems by which recombinant wild-type (wt) viruses or 
viruses lacking NSs expression (ΔNSs) were generated. By comparing wt and ΔNSs infected 
cells, the main function was determined to be the inhibition of the antiviral type I interferon 
system of mammalian cells [20, 26, 43, 158, 165]. Both wt and ΔNSs viruses induced the 
activation of the antiviral transcription factor interferon regulatory factor 3 (IRF3), but the NSs 
expressing wt virus inhibited type I interferon transcription [82, 160]. The lack of type I 
interferon transcription inhibition by SBV ΔNSs was recently demonstrated to be a good 
vaccine candidate in cattle. The vaccine virus was safe and induced neutralizing antibodies and 
protection against challenge SBV wt [84]. 
 
1.3.1. Other NSs functions 
Besides the main function of orthobunyavirus NSs proteins in inhibiting type I IFN induction 
during infection of mammalian cells, several other functions have been demonstrated. The NSs 
proteins of LACV [19], BUNV [26, 89] and SBV [13, 43] have been reported to decrease host 
cellular translation, inducing a so-called host cell shutoff. The exact mechanism of NSs induced 
host cell shutoff is not known but is thought to be in large parts due to the transcription 
inhibition and to a lesser extent on an as yet un-known second mechanism [64]. 
The NSs protein of BUNV was demonstrated to inhibit the induction of apoptosis [64, 82] while 
the LACV and SBV NSs proteins where demonstrated to induce apoptosis [13, 19, 114]. 
Furthermore, the NSs proteins of the California serogroup viruses, to which LACV belongs, 
were demonstrated to possess sequence-similarities with the C-terminal 2/3 of the Drosophila 
Reaper protein. In agreement with this, both LACV NSs and the Reaper protein induced 
apoptosis in an in vitro system [37]. 
Introduction 
10 
The NSs proteins of BUNV [164] and LACV [18] have both been demonstrated to decrease 
viral RNA synthesis in mammalian cells via an unknown mechanism. However, BUNV NSs 
was demonstrated to have no effect on viral RNA synthesis in insect cells [83]. 
Orthobunyaviruses infect both mammalian and insect cells, but the function of the NSs during 
infection of insect cells is not well known. The NSs proteins of both LACV and BUNV did not 
have any effect on host cell transcription in insect cells [152, 160]. However, both LACV and 
BUNV NSs have been described to play a role in subverting the insect cell antiviral RNAi 
system [20, 141, 147]. 
 
1.4. Innate immunity 
The initiation of the innate immune response is dependent on the recognition by cellular pattern 
recognition receptors (PRRs) of so-called pathogen-associated molecular patterns (PAMPs), 
which for viruses are primarily nucleic acids [74]. Currently three families of PRRs have been 
described that recognize RNA viruses: toll-like receptors, nucleotide-binding oligomerization 
domain-containing (NOD)-like receptors and retinoic acid-inducible gene I (RIG-I)-like 
receptors (RLRs) [74, 167]. The ribonucleoprotein complexes of both LACV and the 
phlebovirus RVFV have been demonstrated to be recognized by a member of the RLR family 
[166], why a more detailed description of this pathway of innate immune induction will be 
given. 
 
1.4.1. The RLR pathway 
The RLR family consist of three proteins: melanoma differentiation associated factor 5 
(MDA5), laboratory of genetics and physiology 2 (LGP2) and retinoic acid-inducible gene I 
(RIG-I). MDA5 and LPG2 both recognize long double-stranded RNA [74], while RIG-I 
recognizes 5’ triphosphorylated double-stranded RNA [167]. The panhandle structures on 
LACV and RVFV ribonucleoprotein complexes contains both double-stranded RNA and a 5’ 
triphosphate, which was determined to be recognized by RIG-I [166]. Upon PAMP recognition 
by RIG-I a conformational switch occurs, exposing two caspase-recruiting domains (CARDs) 
that is responsible for downstream signalling, via CARD-CARD interaction, with the 
mitochondrial antiviral signalling protein (MAVS), located in the outer mitochondrial 
membrane [74, 167]. MAVS is a platform to which other downstream factors are recruited, 
among others TNF receptor-associated factor 3/6 (TRAF3/6) [74]. TRAF3/6 interacts with the 
complex of TANK-binding kinase 1 and inhibitor of kappa light polypeptide gene enhancer in 
B-cells kinase epsilon that then phosphorylates the antiviral transcription factor IRF3. The now 
activated IRF3 homodimerizes and translocates to the nucleus where it binds to eg. the IFN-β 
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promoter [61, 90]. The IRF3 dimer bound to the promoter can then recruit RNA polymerase II 
(RNAPII) for transcription [48]. The MAVS/TRAF3 complex also activates the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) pathway, allowing NF-κB to 
translocate into the nucleus where it promotes the transcription of pro-inflammatory genes [68, 
69]. Furthermore, NF-κB is also required, in addition to IRF3 and a third transcription factor 
AP-1, for transcription of IFN-β mRNA [40, 48, 90]. 
 
1.4.2. Interferons and their signalling 
Three classes of interferons (IFN); type I, type II and type III, have been described [131]. Type 
II IFN consists of the single IFN-γ, that is primarily expressed by, and act on, immune cells 
[131]. Type III IFN consists of the four IFN-λ1-4 while type I interferon consists of a single 
IFN-β and 14 IFN-α isoforms [90, 131]. Both type I and III interferon induces the expression of 
interferon stimulated genes (ISG) by binding to their respective receptors, which is the case of 
type I IFN is the IFN-α receptor expressed on almost every cell [61, 131]. Binding of type I IFN 
to its receptor induces a Janus kinase (JAK)/Signal Transducers and Activators of Transcription 
(STAT) signalling pathway [61, 131]. Type I IFN binding to its IFN-α receptor activates 
STAT1/2 proteins, which are phosphorylated and heterodimerizes [11, 170]. The STAT1/2 
heterodimer associates with IRF9, after which the complex translocate to the nucleus where it 
binds to promoters of ISGs containing IFN-stimulated response elements [11, 170]. 
 
1.4.3. Interferon stimulated genes 
Type I interferon signalling induces the expression of around 300 interferon stimulated genes 
(ISGs). The ISGs have different functions e.g. direct antiviral effects, cell-to-cell 
communication or regulation of the response to the infection [41, 62, 72]. Most of the proteins 
involved in recognition and downstream signalling, described above, are all ISGs. Some 
examples and functions of ISGs restricting orthobunyavirus infection will be given [31, 117]. 
RIG-I is expressed at a constitutive low level, but is up-regulated by IFN stimulation, to detect 
and initiate signalling upon recognition of 5’ triphosphorylated double-stranded RNA in the 
cytoplasm [166, 167]. RIG-I induced singling leads to the induction of IRF7 expression. IRF7 is 
highly homologous to IRF3, but has broader activation ability by inducing transcription of both 
IFN-β and IFN-α genes that potentiating the antiviral response [71, 97, 126]. The human 
homolog of murine Myxovirus resistance 1 protein, the MxA protein, has a potent antiviral 
effect against both orthobunyaviruses and phleboviruses [63]. Both in vitro and in vivo 
overexpressed MxA severely reduces viral titers, by inhibiting viral replication [49], and 
increases survival of infected mice [66]. The inhibition of viral replication is partially due to 
sequestration of the N protein into the COP-I compartment, between the smooth ER and Golgi 
Introduction 
12 
[81, 123]. Orthobunyaviruses infections activate the antiviral protein kinase R (PKR) [146]. 
PKR recognizes and is activated by double stranded RNA. Activated PKR-homodimers 
phosphorylate the eukaryotic translation initiation factor 2 α, thereby inhibiting cellular 
translation [101]. 
 
1.5. Cellular Transcription 
Expression of any protein, be it ISGs or constitutively expressed proteins, initiates with the 
transcription of the gene. Three mammalian RNA polymerase types (RNAP types): I, II and III 
have been described that transcribes different RNAs [169]. RNAP type I synthesises ribosomal 
RNA, RNAP type II synthesises mRNAs and non-coding RNAs and the RNAP type III 
synthesises tRNAs. All three polymerases are multisubunit complexes; RNAPI (14 subunits), 
RNAPII (12 subunits), RNAPIII (17 subunits), where five of the subunits are shared between 
the three polymerases [171]. Most studies on structure, assembly and function have been 
performed on RNAPII [169, 171]. The 12 subunits of RNAPII are called RPB 1 to 12, where 
the number indicates the size in a falling scale 1 being the largest subunit. The assembly of the 
RNAPII complex occurs in the cytoplasm, aided by several proteins, and have been 
demonstrated to be crucial for its function [22, 169, 171]. None of the RNAPII subunits have a 
nuclear localization signal (NLS) which is instead provided by interacting proteins [32, 46, 
171]. 
 
1.5.1. Transcription preinitiation complex assembly 
The induction of transcription by RNA polymerase II starts with assembly of the transcription 
preinitiation complex (PIC) composed of RNAPII and general transcription factors [153]. The 
nomenclature of the general transcription factors are: transcription factor (TF) followed by the 
Roman numeral II (for RNAPII) and finally a letter A – H [153]. The initiation of PIC assembly 
is largely driven by cell and tissue specific transcription factors. These transcription factors bind 
to their sequence in the gene promoter, followed by recruitment of the general transcription 
factors and RNAPII [6]. However, several of these specific transcription factors do not directly 
interact with the PIC components. Instead the interaction is mediated by the Mediator complex 
composed of 26 MED subunits of highly dynamic composition. The Mediator complex assists 
both during PIC assembly and throughout the RNAPII transcription cycle [6, 39]. The assembly 
of the PIC starts with the recruitment/recognition of the TATA-box in the core promoter by the 
TATA binding protein, a subunit of TFIID [153]. A sequential recruitment and assembly of the 
PIC then follows with the order of recruitment being: TFIIA-TFIIB-RNAPII-TFIIF-TFIIE-
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TFIIH. Extensive co-operation between the general transcription factors assures that RNAPII is 
correctly positioned, the transcription bubble formed and transcription initiated [153]. 
 
1.5.2. The RPB1 CTD 
The largest subunit of RNAPII, RPB1, contains the catalytically active centre, and possesses a 
C-terminal domain (CTD) that is essential for cell viability, but not for the direct catalytic 
function of RNAPII [42]. The CTD is composed for heptad repeats with the consensus sequence 
tyrosine-serine-proline-threonine-serine-proline-serine (Y1S2P3T4S5P6S7) conserved from yeast 
to mammals. However the amount of repeats varies between organisms: while mammals have 
52 repeats, the yeast S. cerevisiae have 26 [42]. The CTD serves as a platform to which different 
factors bind successively throughout the RNAPII transcription cycle. The recruitment if these 
factors are regulated by post-translational modifications of the CTD: Y1, T4 and S2/5/7 can be 
reversibly phosphorylated, T4 and S5/7 can be dynamically O-glycosylated and P3/6 can isomerize 
to the cis- or trans-conformation [42, 67, 177]. In total 10368 possibilities of CTD 
modifications exist, however some modifications exclude others so the possible combinations in 
vivo are not known. Modelling and experimental data suggest that phosphorylation of the CTD 
makes the structure more extended, allowing interactions with transcription factors and mRNA 
modifying proteins [42, 67, 177]. Two main forms of RPB1 can be detected by Western blot: 
the faster migrating RPB1 IIA (IIA) form and the slower migrating RPB1 IIO (IIO) form. The 
difference in the mobility of the two forms is due to post-translational modifications of the CTD 
[42]. In the RNAPII that is recruited to the PIC, RPB1 is in the IIA form, which is then post 
translationally modified into the transcriptionally active IIO form. The post-translational 
modifications of RPB1 CTD is highly dynamic and reversible where the most studied 
modifications are the phosphorylation and de-phosphorylation of S2 and S5 [42, 67, 177]. CTD 
serine 5 is phosphorylated by the TFIIH subunits cyclin-dependent kinase 7 (CDK7) and de-
phosphorylated by the phosphatase Ssu72. CTD serine 2 is phosphorylated by the positive 
transcription elongation factor b (P-TEFb) subunit CDK9 while it is de-phosphorylated by the 
phosphatase Fcp1 [42]. Phosphorylated CTD serine 5 (CTDpSer 5) and CTD serine 2 
(CTDpSer 2) are both IIO forms of RPB1. CTDpSer 5 is a marker for transcriptionally initiated 
RNAPII, while CTDpSer 2 is a marker for transcriptionally elongating RNAPII [42, 67, 177]. 
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1.6. Orthobunyavirus NSs inhibit transcription elongation 
Incoming ribonucleoprotein complexes of LACV were demonstrated to activate RIG-I [166] 
and both LACV and BUNV infection lead to activation of the antiviral transcription factor IRF3 
[82, 160]. However, the type I IFN induction was inhibited in wt Orthobunyavirus infected cells 
at the later stage of RNAPII transcription elongation [152]. 
The BUNV NSs inhibits the phosphorylation of RPB1 CTD serine 2 [152], which have been 
proposed to be mediated by NSs interaction with the MED8 subunit of the Mediator complex 
[89]. The interaction domain on the NSs was mapped to the very C terminus of the protein. 
Indeed, a rescued BUNV expressing the first 83 amino acid residues of the NSs was unable to 
inhibit both general and IFN-β transcription [89]. However, a BUNV mutant with a truncated 
NSs lacking the first 22 N-terminal amino acids was also deficient in IFN-β inhibition and CTD 
serine 2 blockade. This indicated that the BUNV NSs-inhibition of serine 2 phosphorylation and 
innate immune activation, is dependent not only on the C-terminal MED8 interaction domain, 
but also other parts of the NSs protein [156]. 
Another mechanism of inhibiting RNAPII transcription elongation was demonstrated for the 
LACV NSs protein. LACV NSs induces the proteasomal degradation RPB1 CTDpSer 2 [160]. 
Similarities between LACV wt infection and the DNA damage response (DDR) were noted, 
where both NSs and DDR induced degradation of RPB1 in transcription-elongating RNAPII. In 
addition to the RPB1 degradation also other markers of the DDR were seen in LACV wt 
infected cells such as pak6 transcription and serine 139 phosphorylation of histone H2AX [160]. 
A similar, but slightly delayed, proteasomal degradation of RPB1 was recently reported in SBV 
wt-infected cells [13]. The SBV NSs function, in inducing the proteasomal degradation of 
RPB1, was mapped to the C terminal part of the protein, by ectopic expression of 6 NSs mutants 
at conserved positions [13]. 
To further the understanding of LACV NSs induced degradation of RPB1 CTDpSer 2, attempts 
were made in the group of Prof. Friedemann Weber to find host cell interactors of the NSs 
protein. In in vitro pull down experiments, with components of E3 ligases due to the 
proteasomal-dependent degradation, the Elongin C protein was identified as a possible 
interaction candidate of LAVC NSs (unpublished, see [159]). 
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1.7. The Elongin C protein 
1.7.1. The Elongin complex 
Several factors have been shown to either promote or inhibit RNAPII transcription elongation 
[38]. One of the factors promoting RNAPII transcription elongation is the Elongin complex, 
composed of the three subunits Elongin A (110 kDa), Elongin B (18 kDa) and Elongin C (14 
kDa) [9]. In vitro the heterotrimeric Elongin complex was demonstrated to increase the RNAPII 
transcription elongation rate by 5-fold, compared to reactions without the Elongin complex [9, 
24, 25]. However, the Elongin complex had no effect on RNAPII initiation or synthesis of the 
first 9 mRNA nucleotides [25, 100]. The Elongin A subunit alone stimulated transcription 
elongation in vitro, while neither Elongin B nor C alone had any effect on RNAPII 
transcription. The combination of Elongin A and C increased transcription elongation, 
compared to Elongin A alone, while Elongin B had no effect. Elongin A was therefore 
concluded to be the transcriptionally active subunit while Elongin C potentiates the effect. 
Elongin B had no effect on the function of Elongin A but was seen to stabilizing the Elongin 
complex [9]. 
The interactions between the three subunits of the Elongin complex are dependent on the 
Elongin C subunit. Elongin B and C form a stable complex, Elongin B/C, that can activate 
Elongin A, however Elongin B does not interact with Elongin A [9]. Elongin C interacts with 
Elongin B via the N terminal amino acid residues 19 to 30, while the extreme C terminal part of 
Elongin C is needed for full Elongin complex formation (Elongin A/B/C interaction) and both 
the Elongin B/C and C terminal regions are needed to increase Elongin A activity on RNAPII 
[149]. Elongin A interacts with Elongin C via its so-called BC box motif, 
(STP)Lxxx(CSA)xxxɸ [93], which is shared between different Elongin B/C interactors e.g. the 
Von Hippel Lindau (VHL) [10], Cullin 2 and Cullin 5 protein [78]. 
Functional studies on the Elongin complex have focused on the Elongin A proteins since this is 
the transcription-active subunit. Elongin A was demonstrated to be important in the 
transcription of stress response genes in both mammalian [79] and Drosophila cells [54]. 
Mammalian and Drosophila Elongin A interacted with RPB1, with a preferred interaction of 
mammalian Elongin A with RPB1 CTDpSer 5. However, only partial co-localization was noted, 
indicating that Elongin is not a general transcription elongation factor but is needed for specific 
sets of genes [54, 79]. Knockout of Elongin A in mice demonstrated the vital role of the Elongin 
complex during development, since knockout embryos died 10-13 days post-gestation. In these 
embryos a poor development of the CNS was seen and induction of apoptosis was noted [99]. A 
partial explanation for the embryonic lethality in Elongin A knockout mice was the lack of stem 
cell differentiation into neurons, normally induced by retinoic acid. Indeed, by microarray on 
Elongin A knockout stem cells, genes involved in neuronal development were significantly 
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down-regulated. The down regulation correlated with a lack of transcriptionally elongating 
RNAPII on retinoic acid inducible genes, which was rescued by supplementing the cells with 
Elongin A [175]. 
 
1.7.2. Ubiquitin E3 ligases 
One of the major pathways of protein degradation in the cell is the ubiquitin/proteasome system 
[116]. The protein substrate to be degraded is ubiquitinated in a multistep process involving at 
least 3 enzymes: the ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2) 
and the ubiquitin ligase (E3) [116]. The E1 activate the ubiquitin protein in an ATP-dependent 
reaction, after which the activated ubiquitin is transferred to the E2. The E3 ligase interacts with 
both the substrate to be ubiquitinated and the E2, orienting and bringing the substrate into close 
proximity of the E2 [116, 173]. The first step is the monoubiquitination of the substrate, where 
the activated C terminus of the ubiquitin protein is covalently attachment to a lysine residue on 
the substrate protein. This initial monoubiquitination is the first step in polyubiquitination, 
where the C terminus of a new ubiquitin protein is covalent attached to one of the seven lysine 
residues or the N terminus of the initial ubiquitin [173]. Polyubiquination chains containing 
lysine 48-linked ubiquitin’s, marks the substrate for proteasomal degradation. One of the main 
E3 ligase families contains a Cullin protein [5, 116, 173], for which Cullin 2 or 5 both have 
been demonstrated to form E3-ligases containing Elongin B/C [93]. 
Cullin 2 forms an E3 ligase containing the tumour suppressor protein VHL, Elongin B/C and 
Rbx1 [78, 93, 111]. In vitro studies on this complex had ubiquitin E3 ligase activity [73], where 
the substrate, by VHL interaction, was determined to be the hypoxia stabilized transcription 
factor HIF-1 [94]. Cullin 2 has also been determined to interact with the MED8 subunit, of the 
Mediator complex, forming an E3 ligase containing Elongin B/C, and Rbx2. This E3 ligase was 
able to perform polyubiquitination, however no specific substrate was identified [27]. Cullin 5 
interacts with suppressor of cytokine signalling (SOCS) proteins, forming an E3 ligase 
containing Elongin B/C and Rbx2. However, substrates for these E3 ligases have not been 
identified [77, 78, 93]. 
 
1.7.3. Transcription–coupled nucleotide excision repair 
If transcriptionally active RNAPII encounters a damage/block in the DNA the polymerase stalls 
at this position. To resolve the DNA damage/block the process of transcription–coupled 
nucleotide excision repair (TC-NER) is initiated. During TC-NER, stalled RNAPII is 
recognized by Cockayne Syndrome B protein which signals for induction of the repair pathway. 
To make room for the repair complex formed on the damage DNA, RNAPII can either 
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backtrack on the DNA, to be able to resume transcription after the damage has been repaired, or 
the RNAPII complex is disassemble via ubiquitin mediated proteasomal degradation of the 
largest subunit RPB1 [86, 161]. The DNA damage induced ubiquitinylation of RPB1 is a highly 
organized process in which two E3 ligases have been confirmed to be involved. 
The yeast E3 ligase Rsp5 and its mammalian homolog NEDD4 have been demonstrated to 
support ubiquitinylation of RPB1. In vitro, Rsp5 was demonstrated to preferentially 
ubiquitinylate RPB1 in transcriptionally elongating RNAPII stalled at damaged DNA in 
comparison to free RPB1 or RPB1 in transcriptionally elongating RNAPII on undamaged DNA. 
Rsp5 was further demonstrated to interact with phosphorylated CTD [143, 144]. Also human 
NEDD4 was confirmed to be the primary E3 ligase targeting RPB1 in RNAPII stalled by UV 
damage [7]. 
The second E3 ligase, determined to be needed for polyubiquitination and subsequent 
degradation of RPB1, contains the yeast homologs of Elongin C, Elongin A, Cullin 5, and 
probably Rbx1 [124, 125]. In mammals, an ubiquitin E3 ligase consisting of Elongin A/B/C-
Cullin 5-Rbx2 or Rbx1 was detected, which in vitro polyubiquitinylated RPB1 [174]. Cullin 5 
and Elongin A were both present in the nucleus, and after UV-treatment a strong co-localization 
between the two protein was seen [174] at sites of DNA damage [168]. Elongin A mainly 
interacted with, and induced degradation of, the CTDpSer 5 form of RPB1, upon DNA damage 
[79, 168, 174]. 
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2. Aim of the thesis 
Infection of orthobunyavirus causes a rapid induction of the antiviral type I IFN system [20, 26, 
43], due to RIG-I recognition of incoming RNPs [166] leading to IRF3 dependent transcription 
of type I IFN [20, 152]. To counteract the innate immune induction, orthobunyaviruses express 
the NSs protein which rapidly inhibits host cell transcription, of both antiviral and constitutively 
expressed genes [152, 160]. LACV NSs was demonstrated to inhibit host cell transcription by 
inducing the proteasomal degradation of the largest subunit, RPB1, in transcriptionally 
elongating RNA polymerase II. In attempts to find host cell interaction candidates of LACV 
NSs, the Elongin C protein was identified previously. Elongin C was a promising candidate 
since it has been demonstrated to be a subunit of both, the Elongin complex which increases 
RNA polymerase II transcription elongation rates, and several cellular and viral ubiquitin E3 
ligases. 
The objective of my thesis was to characterise the LACV NSs interaction with Elongin C, and 
the role this interaction might have on the function of the NSs protein. Furthermore, loss-of-
function mutants of LACV NSs where used to map functional domains of the protein. 
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3. Material 
 
3.1. Cell lines 
Table 1. Cell lines used for experiments. 
Name
a
 Organism Tissue type 
HuH-7 
(JCRB: 0403) 
Homo sapiens, Human Hepatocellular carcinoma 
A549 
(ATCC: CCL-185) 
Homo sapiens, Human Lung Carcinoma 
HEK-293 
(ATCC: CRL-1573) 
Homo sapiens, Human Embryonic kidney 
BHK-21 
(ATCC: CCL-10) 
Mesocricetus auratus, Syrian/Golden hamster Kidney fibroblast 
Vero76 
(ATCC: CRL-1587) 
Cercopithecus aethiops, Givet or African 
green monkey 
Kidney epithelium 
CV-1 
(ATCC: CCL-70) 
Cercopithecus aethiops, Givet or African 
green monkey 
Kidney fibroblast 
a
 the ATCC or JCRB catalogue nr. is given as reference. The cells were kept in culture for several passages and 
might therefore not perform as cells directly received from ATCC or JCRB. 
 
3.2. Viruses 
Table 2. Viruses available at the beginning of the work. 
Virus Name Description 
La Crosse virus a LACV wt Recombinant LACV wt rescued via reverse 
genetics [19]. 
La Crosse virus ΔNSs a 
 
LACV ΔNSs Recombinant LACV not expressing the NSs 
protein. Rescued via reverse genetics where the 
initial two start codons in the NSs ORF were 
exchanged to two threonine codons and the 
third codon to a stop codon. These exchanges 
did not cause any change in the N ORF [19]. 
Vesicular Stomatitis Virus a VSV Vesicular Stomatitis Virus, strain: Indiana 
Rift Valley fever virus-CF-NSs b 
 
ZH-CF-NSs Recombinant wt RVFV rescued via reverse 
genetics. The NSs protein has been tagged with 
a C-terminal 3×Flag for detection [58] c. 
Rift Valley fevr virus-3×NF-ΔMx b 
 
ZH-3×NF-ΔMx Recombinant RVFV where the NSs has been 
replaced by the first 105 amino acids of the 
MxA protein tagged with an N-terminal 3×Flag 
for detection [58] c. 
Rift Valley fever virus-3×NF-NSsLAC b 
 
ZH-3×NF-NSsLAC Recombinant RVFV where the NSs has been 
replaced by the LACV NSs protein tagged with 
an N-terminal 3×Flag for detection [58] c. 
a experiments with these viruses were performed under BSL-2 conditions. b experiments with these viruses were 
performed under BSL-3 conditions. c the referenced publication do not illustrate the rescue of these particular viruses 
but gives the explanation of the cloning and rescue procedure of them. 
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Table 3. Rift Valley fever virus (RVFV) expressing La Crosse virus (LACV) NSs mutants, 
generated during the work for this thesis. 
Name
a
 Virus Description 
rRVFV LAC L11A RVFV Recombinant RVFV where the RVFV NSs has been replaced by the 
LACV NSs L11A mutant tagged with an N-terminal 3×Flag. 
rRVFV LAC 18to22A RVFV Recombinant RVFV where the RVFV NSs has been replaced by the 
LACV NSs 18to22A mutant tagged with an N-terminal 3×Flag. 
rRVFV LAC 33to38A RVFV Recombinant RVFV where the RVFV NSs has been replaced by the 
LACV NSs 33to38A mutant tagged with an N-terminal 3×Flag. 
rRVFV LAC 41to48A RVFV Recombinant RVFV where the RVFV NSs has been replaced by the 
LACV NSs 41to48A mutant tagged with an N-terminal 3×Flag. 
rRVFV LAC 57to59A RVFV Recombinant RVFV where the RVFV NSs has been replaced by the 
LACV NSs 57to59A mutant tagged with an N-terminal 3×Flag.  
rRVFV LAC 67to71A RVFV Recombinant RVFV where the RVFV NSs has been replaced by the 
LACV NSs 67to71A mutant tagged with an N-terminal 3×Flag.  
rRVFV LAC 78to87A RVFV Recombinant RVFV where the RVFV NSs has been replaced by the 
LACV NSs 78to87A mutant tagged with an N-terminal 3×Flag. 
a all experiments with these viruses were performed under BSL-3 conditions 
 
3.3. Primers 
Table 4. Cloning and sequencing primers. 
Lab. Collection Nr. Primer Name Sequence Description 
#45 pI.18_for2 TCCATGGGTCTTT
TCTGCAG 
Forward primer for sequencing of 
insert in pI.18 plasmid (see Table 5. 
Plasmids used in transfection 
or rescue experiments.Table 5) 
#46 pI.18_rev2 GTGACACGTTTAT
TGAGTAGG 
Reverse primer for sequencing of 
insert in pI.18 plasmid (see Table 5) 
RVFV #44 3'XhoI-ZH548_N GACACTCGAGTTA
GGCTGCTGTCTTG
TAAGCCTGA 
Reverse primer for amplifying the 
ORF of RVFV N. 
RVFV #78 HHcS_ZHPro4rev TCTGTCGCCGGCC
ACACAAAGACCC
CCTAGTGCT 
Forward primer for sequencing of 
RVFV NSs ORF. 
RVFV #97 5'Esp3I-ZH548_N GACAGACGTCTCA
CATGGACAACTAT
CAAGAGCTTGCGA
T 
Forward primer for amplifying the 
ORF of RVFV N. 
RVFV #117 3xFlag_5'NcoI GACAGACGTCTCA
CATGGACTACAAA
GACCATGACGG 
Forward primer annealing to Flag 
sequence. Contains a 5’ Esp3I site 
that upon digestion generates a NcoI 
site. 
RVFV #118 LACV_NSs 3'XhoI GACAGACCGTCTC
TTCGACTAAATAC
CCAGATAATCTGT
GG 
Reverse primer anneling to the 3’end 
of LACV NSs. Contains a 3’ Esp3I 
site that upon digestion generates a 
XhoI site 
RVFV #183 NSs diagnostic RVFV GGTGGGGCAGCCT
TAACC 
Reverse primer for NSs expression- 
and sequence-analysis 
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3.4. Plasmids 
Table 5. Plasmids used in transfection or rescue experiments. 
Lab. Collection Nr. Plasmid Name Antibiotic resistance Description 
#25 pI.18-HA-PKR-DN Ampicillin Contains a dominant negative 
region of PKR (nucleotide +4 
to +524 of the PKR ORF, 
NM_002759.3). Tagged with a 
5’HA. 
#26 pI.18_RVFV_L Ampicillin Expression plasmid containing 
the ORF of RVFV L protein 
(nucleotides +16 to +6302 of 
the RVFV L segment, strain 
ZH-548, DQ375403.1). 
#28 pI.18_RVFV_N Ampicillin Expression plasmid containing 
the ORF of RVFV N protein 
(nucleotide +36 to +1062 of 
the RVFV S segment, strain 
ZH-548, DQ380151.1). 
#36 pHH21_RVFV_vL Ampicillin Rescue plasmid containing the 
full-length RVFV L segment 
in viral sense orientation 
(RVFV, strain ZH-548, 
DQ375403.1) 
#37 pHH21_RVFV_vM Ampicillin Rescue plasmid containing the 
full-length RVFV M segment 
in viral sense orientation 
(RVFV, strain ZH-548, 
DQ380206.1). 
#40 pHH21_RVFV_vN_MCS Ampicillin Rescue plasmid containing the 
full-length RVFV S segment in 
viral sense orientation, NSs 
ORF replaced by a tandem 
cloning site (RVFV S segment, 
strain ZH-548, DQ380151.1). 
#48 pRL-SV40 Ampicillin Contains the ORF of Renilla 
luciferase under the control of 
the SV40 enhancer/promoter 
(Promega, #E2231) 
#77 ISG54-Luc Ampicillin Contains the ORF of Firefly 
luciferase under the control of 
the ISG54 promoter [110]. 
#217 pI.18 3xFLAG-LACV_NSs Ampicillin Contains the ORF of LACV wt 
NSs (strain 
LACV/human/1978, 
EF485033.1) tagged with a 5’ 
3×Flag. 
#219 pI.18 3xFLAG-ΔMx Ampicillin Contains nucleotide +4 to 
+318 of the Mx1 ORF 
(XM_005260978.2) tagged 
with a 5’ 3×Flag. 
#220 pI.18 3xFlag LAC-NSs-
L11A 
Ampicillin Contains the ORF of LACV wt 
NSs where amino acid position 
11 has been changed from a 
leucine to an alanine via site-
directed mutagenesis. Tagged 
with a 5’ 3×Flag. 
#221 pI.18 3xFlag LAC-NSs-
18to22A 
Ampicillin Contains the ORF of LACV wt 
NSs where amino acid position 
18 to 22 has been changed to 
alanines via site-directed 
mutagenesis. Tagged with a 5’ 
3×Flag. 
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#222 pI.18 3xFlag LAC-NSs-
33to38A 
Ampicillin Contains the ORF of LACV wt 
NSs where amino acid position 
33 to 38 has been changed to 
alanines via site-directed 
mutagenesis. Tagged with a 5’ 
3×Flag. 
#223 pI.18 3xFlag LAC-NSs-
41to48A 
Ampicillin Contains the ORF of LACV wt 
NSs where amino acid position 
41 to 48 has been changed to 
alanines via site-directed 
mutagenesis. Tagged with a 5’ 
3×Flag. 
#224 pI.18 3xFlag LAC-NSs-
57to59A 
Ampicillin Contains the ORF of LACV wt 
NSs where amino acid position 
57 to59 has been changed to 
alanines via site-directed 
mutagenesis. Tagged with a 5’ 
3×Flag. 
#225 pI.18 3xFlag LAC-NSs-
67to71A 
Ampicillin Contains the ORF of LACV wt 
NSs where amino acid position 
67 to 71 has been changed to 
alanines via site-directed 
mutagenesis. Tagged with a 5’ 
3×Flag. 
#226 pI.18 3xFlag LAC-NSs-
78to87A 
Ampicillin Contains the ORF of LACV wt 
NSs where amino acid position 
78 to 87 has been changed to 
alanines via site-directed 
mutagenesis. Tagged with a 5’ 
3×Flag. 
 
Table 6. Plasmids generated for rescuing RVFV expressing the indicated LACV NSs mutants. 
Lab. Collection Nr. Plasmid Name Antibiotic resistance Description 
#597 pHH21-RVFV-vN-
LAC-FLAG-NSs 
L11A 
Ampicillin Rescue plasmid containing the 
full-length RVFV S segment in 
which the RVFV NSs was 
replaced by 3×Flag LACV NSs 
L11A. The insert was amplified 
from plasmid #220a. 
#598 pHH21-RVFV-vN-
LAC-FLAG-NSs 
18to22A 
Ampicillin Rescue plasmid containing the 
full-length RVFV S segment in 
which the RVFV NSs was 
replaced by 3×Flag LACV NSs 
18to22A. The insert was 
amplified from plasmid #221a. 
#599 pHH21-RVFV-vN-
LAC-FLAG-NSs 
33to38A 
Ampicillin Rescue plasmid containing the 
full-length RVFV S segment in 
which the RVFV NSs was 
replaced by 3×Flag LACV NSs 
33to38A. The insert was 
amplified from plasmid #222 a. 
#600 pHH21-RVFV-vN-
LAC-FLAG-NSs 
41to48A 
Ampicillin Rescue plasmid containing the 
full-length RVFV S segment in 
which the RVFV NSs was 
replaced by 3×Flag LACV NSs 
41to48A. The insert was 
amplified from plasmid #223a. 
#601 pHH21-RVFV-vN-
LAC-FLAG-
NSs57to59A 
Ampicillin Rescue plasmid containing the 
full-length RVFV S segment in 
which the RVFV NSs was 
replaced by 3×Flag LACV NSs 
57to59A. The insert was 
amplified from plasmid #224 a. 
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#602 pHH21-RVFV-vN-
LAC-FLAG-NSs 
67to71A 
Ampicillin Rescue plasmid containing the 
full-length RVFV S segment in 
which the RVFV NSs was 
replaced by 3×Flag LACV NSs 
67to71A. The insert was 
amplified from plasmid #225 a. 
#603 pHH21-RVFV-vN-
LAC-FLAG-NSs 
78to87A 
Ampicillin Rescue plasmid containing the 
full-length RVFV S segment in 
which the RVFV NSs was 
replaced by 3×Flag LACV NSs 
78to87A. The insert was 
amplified from plasmid #226 a. 
a The indicated ORF was amplified via PCR using primers RVFV #117/#118. The insert was cloned into plasmid #40 
via conventional cloning of Aar1 digested vector and Esp3I digested insert. 
 
3.5. Small interfering RNAs (siRNAs) 
Table 7. siRNAs used for knockdown of the indicated targets. 
Target name siRNA name Supplier Order Nr. GeneSolution Transcript target 
Control All Star Neg. CTRL Qiagen SI03650318   
Elongin C Hs_TCEB1_1 
Hs_TCEB1_2 
Hs_TCEB1_4 
Hs_TCEB1_5 
Qiagen S100741251 
S100741258 
S100741272 
S103056711 
GS6921 NM_001204857 
NM_001204858 
NM_001204859 
NM_001204860 
NM_001204861 
NM_001204862 
NM_001204863 
NM_001204864 
NM_005648 
Elongin B Hs_TCEB2_1 
Hs_TCEB2_3 
Hs_TCEB2_5 
Hs_TCEB2_6 
Qiagen SI00094591 
SI00094605 
SI03086671 
SI03117016 
GS6923 NM_007108 
NM_207013 
Elongin A Hs_TCEB3_5 
Hs_TCEB3_6 
Hs_TCEB3_7 
Hs_TCEB3_8 
Qiagen SI04152316 
SI04226887 
SI04258422 
SI04309396 
GS6924 NM_003198 
 
3.6. Real time PCR primers 
Table 8. Commercially available primer sets for SYBR Green-based real time PCR. 
Target QuantiTect Primer Name Supplier Order Nr. Detected transcripts 
IFN ß Hs_IFNB1_1_SG Qiagen QT00203763 NM_002176 
IFIT1 (ISG56) Hs_IFIT1_1_SG Qiagen QT00201012 NM_001001887.1 
NM_001548.4 
NM_001270927.1 
NM_001270928.1 
NM_001270929.1 
NM_001270930.1 
Ribosomal 18s RNA Hs_RR18s Qiagen QT00199367 X03205.1 
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Table 9. Primers for real time PCR with SYBR Green-based detection. 
Primer Name Description Sequence Reference 
LACV N forward Detects LACV N RNA GGGTATATGGACTTCTGTG [160] 
LACV N reverse Detects LACV N RNA GCCTTCCTCTCTGGCTTA [160] 
Gamma actin forward Forward primer detecting intron 
3 in human γ-actin. 
GCTGTTCCAGGCTCTGTTCC [36] 
Gamma actin reverse 
 
Reverse primer detecting intron 
3 in human γ-actin 
ATGCTCACACGCCACAACATGC [36] 
 
Table 10. Primers for real time PCR with TaqMan-based detection. 
Primer Name Description Sequence Reference 
RVFL-2912fwdGG Forward primer for detection 
of RVFV L RNA 
TGAAAATTCCTGAGACACATGG [17] 
RVFL-2981revAC Reverse primer for detection 
of RVFV L RNA 
ACTTCCTTGCATCATCTGATG [17] 
RVFL-probe-2950 Probe for detection of RVFV 
L RNA 
6FAM-CAATGTAAGGGGCCTGTG 
TGGACTTGTG-BHQ1 
[17] 
 
3.7. Antibodies 
Table 11. Primary and secondary antibodies used in Western blot. 
Name Species Clonality Supplier Catalogue Dilution 
Anti-acetyl-Histone 3 Rabbit Polyclonal Merck Millipore 06-599 1:500 
Anti-β-Tubulin Rabbit Polyclonal Abcam ab6046 1:500 
Anti-Flag Rabbit Polyclonal Sigma-Aldrich F7425 1:3200 
Anti-RVFV (MP-12) Rabbit Serum Dr. A. Brun, Instituto 
Nacional de Investigación 
Agraria y Alimentaria, 
Madrid, Spain 
 1:2000 
Anti-SIII p15 
(Elongin C) 
Mouse Monoclonal BD Biosciences 610761 1:250 
Anti-TCEB3 
(Elongin A) 
Rabbit Polyclonal Sigma Aldrich HPA005910 1:1000 
CTD-pSer2 Rat Serum Prof. Dr. D. Eick, 
Helmholtz Zentrum, 
München 
 1:500 
CTD-pSer5 Rat Serum Prof. Dr. D. Eick, 
Helmholtz Zentrum, 
München 
 1:500 
Elongin B 
(FL-118) 
Rabbit Polyclonal Santa Cruz Sc-11447 1:250 
LACV N Rabbit Polyclonal Prof. Dr. G. Kochs, 
Institute of Virology, 
Universitäts Klinikum 
Freiburg 
 1:15000 
Pol II (N-20) (RPB1) Rabbit Polyclonal Santa Cruz sc-899 1:500 
Peroxidase-conjugated 
anti-Mouse IgG 
Goat Polyclonal Thermo Fisher 0031430 1901971 1:20000 
Peroxidase-conjugated 
anti-Rabbit IgG 
Goat Polyclonal Thermo Fisher 0031460 1901972 1:20000 
Peroxidase-conjugated 
anti-Rat IgG 
Donkey Polyclonal Jackson ImmunoResearch 712-036-150 1:20000 
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Table 12. Primary and secondary antibodies used in immunofluorescence. 
Name Species Clonality Supplier Catalogue Nr. Dilution 
Anti-Flag Rabbit Polyclonal Sigma-Aldrich F7425 1:500 
Anti-Nucleolin Rabbit Polyclonal Abcam ab22758 1:1000 
Anti-SIII p15 
(Elongin C) 
Mouse Monoclonal BD Biosciences 610761 1:250 
Anti-TCEB3 
(Elongin A) 
Rabbit Polyclonal Sigma Aldrich HPA005910 1:500 
Elongin B 
(FL-118) 
Rabbit Polyclonal Santa Cruz Sc-11447 1:100 
LACV GC Mouse Monoclonal Prof. Dr. F.G. Scarano, 
Departments of Neurology 
and Microbiology, 
University of Pennsylvania 
School of Medicine, 
Philadelphia 
 1:400 
LACV N Rabbit Polyclonal Prof. Dr. G. Kochs, Institute 
of Virology, Universitäts 
Klinikum Freiburg 
 1: 500 
Alexa Fluor 488 
anti-Mouse IgG 
Donkey Polyclonal Life Technologies A21202 1:200 
Alexa Fluor 555 
anti-rabbit IgG 
Donkey Polyclonal Life Technologies A31572 1:200 
Alexa Fluor 555 
anti-mouse IgG 
Donkey Polyclonal Life Technologies A31570 1:200 
Alexa Fluor 488 
anti-rabbit IgG 
Donkey Polyclonal Life Technologies A21206 1:200 
 
3.8. Cell culture 
Table 13. Cell culture and transfection reagents 
Name Supplier Catalogue Nr. 
Avicel FMC BioPolymer  
DMEM, powder, high glucose Gibco – Life Technologies 52100-021 
Dulbecco's Modified Eagle Medium (DMEM) Gibco – Life Technologies 21969-035 
Fetal Bovine Serum (FBS) Gibco – Life Technologies 10270-106 
L-Glutamine (200 mM) Gibco – Life Technologies 25030-024 
Opti-MEM I Reduced Serum Medium Gibco – Life Technologies 31985-047 
Penicillin-Streptomycin (5,000 U/mL) Gibco – Life Technologies 15070-063 
Sodium bicarbonate Thermo Fisher 25080-094 
Sodium pyruvate Sigma S8636-100ML 
Trypsin-EDTA (0.05%) Gibco – Life Technologies 25300-054 
Lipofectamine RNAiMAX Life Technologies 13778-150 
Nanofectin PAA Q051-005 
TransIT-LT1 Mirus MIR 2306 
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3.9. Isolation, cloning and detection of nucleic acids 
Table 14. Cloning reagent, nucleic acid isolation kits and restriction enzymes 
Name Supplier Catalogue Nr. 
E.Z.N.A. Gel Extraction Kit Omega Bio-Tek D2500-02 
QIAquick Gel Extraction Kit (250) Qiagen 28706 
QIAquick PCR Purification Kit (250) Qiagen 28106 
Shrimp Alkaline Phosphatase (SAP) Fermentas EF0511 
T4 DNA Ligase Thermo Scientific EL0014 
E.Z.N.A. Plasmid Midi Kit Omega Bio-Tek D6904-04 
NucleoBond PC100 Macherey-Nagel 740573.100 
E.Z.N.A. Plasmid Mini Kit I Omega Bio-Tek D6943-02 
peqGOLD Plasmid Miniprep Kit peqlab 12-6942-02 
QIAamp Viral RNA Mini Kit (250) Qiagen 52906 
RNeasy Mini Kit (50) Qiagen 74104 
AarI Fermentas ER1581 
Esp3I New England Biolabs R0580S 
 
Table 15. Nucleic acid amplification and detection kits 
Name Supplier Catalogue Nr. 
JumpStart Taq DNA Polymerase Sigma D9307-250UN 
KOD Hot Start DNA Polymerase Calbiochem D2500-02 
QIAGEN OneStep RT-PCR Kit Qiagen 210212 
QuantiTect Reverse Transcription Kit Qiagen 205313 
QuantiTect SYBR Green PCR Kit Qiagen 204143 
SensiMix II Probe Kit Bioline BIO-91002  
 
3.10. Additional chemicals and kits 
Table 16. Additional Chemicals and Kits 
Name Supplier Catalogue Nr. 
2-Mercaptoethanol Sigma-Aldrich M3148 
2-propanol Sigma-Aldrich 33539 
Actinomycin D Sigma-Aldrich A1410 
α-amanitin AppliChem A1485,0001  
Ammonium persulfate Sigma-Aldrich A3678 
Ampicillin-ratiopharm 1,0 g Ratiopharm  L61978  
Bacto agar BD 214010 
Bovine Serum Albumin Sigma-Aldrich A7906 
Bromophenol blue  Sigma-Aldrich  B7021  
Chloroform Merck 102445 
Chromatography paper Kobe 4006052 
Color Protein Standard (Broad Range) New England Biolabs P7712S 
Crystal Violet Sigma-Aldrich C3886  
DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride) Sigma-Aldrich D9542 
DNaseI (RNase free) Thermo Scientific EN0521 
Dual-Luciferase Reporter Assay System Promega E1960 
Ethanol Sigma-Aldrich 32205 
Ethidium bromide Roth 2218.1 
Ethylenediaminetetraacetic acid (EDTA) Roth 8043.2 
FluorSave Reagent Calbiochem 345789 
Formaldehyde Acros Organics 119690025 
Glacial acetic acid  Merck 100063 
Glycerol Roth 3783.2 
Glycin Acros Organics 220910010 
Glycogen Roche 10901393001 
Hydrochloric acid Sigma-Aldrich 30720 
Immobilon-P membrane, PVDF Millipore IPVH00010 
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Leptomycin B USBiological L1671-38B 
Methanol Sigma-Aldrich 32213 
Non-fat dry milk-powder Saliter  
O'GeneRuler 1 kb Plus DNA Ladder  Thermo Scientific SM1343 
Orange DNA Loading Dye (6X) Thermo Scientific R0631  
Parafomaldehyde Roth 0335.3 
Peptone from casein  Merck 107213 
peqGOLD TriFAST Peqlab 30-2020 
Phosphatase Inhibitor Cocktail Set II Calbiochem 524625 
Polyetylenglycol 8000 Sigma-Aldrich P2139 
Potassium chloride (KCl) Sigma-Aldrich 31248 
Protease inhibitor cocktail (COMPLETE) Roche 04 693 116 001 
Protein Assay Dye Reagent Concentrate Biorad 500-0006 
RiboLock RNase Inhibitor Thermo Scientific EO0381 
Rotiphorese Gel 30 Acrylamid-Bisacrylamid (37,5:1) Roth 3029.1  
SDS (Dodecyl sulfate sodium salt) Roth 4360.2 
Sodium Chloride (NaCl) Sigma-Aldrich 31434 
SuperSignal West Chemiluminescent Substrate Thermo Scientific 34096 
TEMED (N,N,N′,N′-Tetramethylethylenediamine) Sigma-Aldrich T9281 
T-PER Tissue Protein Extraction Reagent Thermo Scientific  78510  
Trichloroacetic acid Sigma-Aldrich T4885 
Tris(hydroxymethyl)aminomethane Acros Organics 140500010 
Triton X-100  Sigma-Aldrich T9284 
Tween 20 Sigma-Aldrich P7949 
Yeast extract Roth 2363.3 
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4. Methods 
 
4.1. Cell-based methods 
4.1.1. Cell culture 
All cell lines were cultivated in the cell culture medium Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with Foetal Bovine Serum (FBS) to a final concentration of 10 %, 2 
mM L-glutamine, 50 units/ml penicillin and 50 µg/ml streptomycin. The cells were propagated 
at 37 °C and 5 % CO2. For sub-culturing, the cell monolayer was washed once in phosphate 
buffered saline (PBS) and detached from the culture flask by trypsin-EDTA treatment. The 
detached cells were resuspended in cell culture medium and used further for seeding in new 
flasks/wells. 
 
4.1.2. Plasmid transfections 
Transfection of plasmids into attached cells was performed using Nanofectin (PAA) or TransIT-
LT1 (Mirus) according to manufacturer’s instructions. Shortly, the volume of plasmid(s) needed 
for the experiment was added to OptiMEM, followed by the transfection reagent. After careful 
mixing the solution was incubated at room temperature for 15 min. The transfection solution 
was then added drop-wise into the serum-containing cell culture medium in each well, evenly 
distributed in the medium by mild shaking using a HS 250 B shaker (IKA Labortechnik) for 5 
min at room temperature. After 4 h of incubation at 37 °C (5 % CO2) the cell culture medium 
was exchanged by fresh medium and the cells further incubated. 
 
4.1.3. siRNA transfection 
For siRNA knockdowns, the transfection reagent Lipofectamine RNAiMAX (Life 
Technologies) was used according to the manufacturer’s instructions. The knockdowns were 
based on a pre-mixed siRNA solution (GeneSolution) containing four siRNAs directed against 
four different sequences in the target transcript. The siRNA solution was diluted in OptiMEM, 
to get a 50 nM final concentration of in the well. The solution was mixed thoroughly, followed 
by the addition of the appropriate volume of transfection reagent. The solution was thoroughly 
mixed again and then incubated for 15 min at room temperature. The so-called “reverse 
transfection” method was then performed. The siRNA solution was added to the empty well 
followed by seeding of the cells, suspended in an adjusted volume of cell culture medium to get 
a final concentration of 50 nM siRNA. Following a 4 h incubation at 37 °C (5% CO2), to allow 
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for cell-attachment, the cell culture medium was exchanged by fresh medium and the cells 
further incubated for 72 h. The knockdown procedure described above was then performed an 
additional time, the day before infection, where the desired amounts of cells for the experiment 
were seeded. 
 
4.2. Virus-based methods 
4.2.1. Virus propagation and sampling 
All infections were performed in the Institute for Virology, Philipps University Marburg, under 
BSL-2 conditions (for LACV) or BSL-3 conditions (for RVFV). The cells were first washed 
once with PBS and the virus inoculum, diluted in OptiMEM to reach the desired multiplicity of 
infection (MOI), was then added to the cells. Infections were performed by incubating the 
flask/plate at 37 °C (5 % CO2) for 1 h with careful shaking backwards and forwards and from 
side to side every 10 min. The inoculum was removed and fresh cell culture medium added. As 
controls, in parallel to the infections, the cellular transcription was inhibited using either the 
specific RNAPII inhibitor α-amanitin or the general transcription inhibitor Actinomycin D. α-
amanitin binds close to the active centre of RPB1 and locks the trigger loop needed for correct 
addition of nucleotides in an open inactive conformation, thereby inhibiting RNA polymerase II 
transcription [28, 30]. Actinomycin D is a general RNA synthesis inhibitor through its ability of 
intercalating the DNA [115, 139]. The control cells where treated as mock cells during virus 
infection, but post adsorption of the viruses cell culture medium containing the different 
inhibitors were added to the cells. In experiments where the nuclear export via CRM1 was 
inhibited, Leptomycin B (LMB) was used. LMB specifically inhibits CRM1 by covalently 
binding to its Cys-529 residue [85]. The cells were pre-treated for 1 h with LMB and then 
infected. After infection, LMB containing cell culture medium was added. All cells were 
incubated at 37 °C (5 % CO2) for the indicated time of the experiment. 
 
4.2.2. Growing virus stocks 
The same procedure for growing virus stocks was used under BSL-2 and BSL-3 conditions. 
Sub-confluent Vero 76 cells (25 – 30%) seeded in a T175 flask were washed and infected with 
5000 plaque forming units (pfu) of the virus, diluted in OptiMEM. Following infection, and 
removal of the inoculum, fresh cell culture medium was added and the cells maintained at 37 °C 
(5 % CO2) for 72 h. The virus-containing supernatant was clarified by centrifugation at 1500 
rpm for 5 min at room temperature using a Multifuge 4KR centrifuge (Heraeus). The virus stock 
was then aliquoted and stored at -80 °C. 
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4.2.3. Virus titration 
Plaque assay with Avicel overlay was used to titrate the virus stocks, under both BSL-2 and 
BSL-3 conditions. One aliquot of the virus stock was thawed and a dilution series in duplicates, 
from 10
-1
 – 10-8, was performed in OptiMEM. Confluent CV-1 cells were washed and dilutions 
10
-3
 – 10-8 were added to successive wells and the cells were infected for 1 h. The inoculum was 
removed and DMEM supplemented with 1 mM sodium pyruvate, 3.7 g/l sodium bicarbonate, 
10 % FBS, 2 mM L-glutamine, 50 units/ml penicillin, 50 µg/ml streptomycin and 1.5 % Avicel 
was added as an overlay. The cells were then incubated for 72 h at 37 °C (5 % CO2). To assure 
that the cell layer did not detach during staining, a 20 % (w/v) trichloroacetic acid (Sigma-
Aldrich) dissolved in ddH2O was drop-wise added to the overlay before washing the cells. After 
thorough, but careful washing, the cells were incubated in staining solution (0.75 % crystal 
violet, 3.75 % formaldehyde, 20 % ethanol, 1 % methanol) for 10 min. The staining solution 
was discarded, the cell layer washed twice with PBS and the plaques were counted. For 
calculation of the stock titer the dilution factor and the volume of the inoculum were accounted 
for. 
 
4.2.4. Preparation of BSL-3 samples 
The procedure for bringing out samples from the BSL-3 security laboratory is described in 
“SOP Inaktivirung von umhüllten Viren (University of Marburg, UMR104)”. 
For protein samples, the cell monolayer were washed once with PBS and then lysed in lysis 
buffer containing one part T-PER (Thermo Scientific) and one part Sample buffer (35.75 mM 
Tris-HCl (pH 6.8), 7.15 % Glycerol, 1.425 % SDS, 1.075 mM Bromphenol Blue) and 
supplemented with Complete Protease inhibitor (Roche) and Phosphatase Inhibitor Cocktail Set 
II (Calbiochem). The cell lysate was then boiled, 100 °C for 10 min, followed by transfer to a 
new Eppendrof tube. The protein sample was brought out of the BSL-3 laboratory via a 5% 
Microchem Plus bath. Outside the sample was boiled once more, at 100 °C for 10 min, and then 
stored at -20 °C until analysis. 
RNA samples, either viral RNA from cell culture medium or total cellular RNA, were brought 
out of the BSL-3 laboratory using QIAamp Viral RNA Mini Kit (Qiagen) or RNeasy Mini Kit 
(Qiagen), respectively. Viral RNA, from cell culture medium, was isolated in AVL buffer while 
total cellular RNA was isolated in RLT buffer. Both buffers contain 4 M guanidinium 
thiocyanate and were incubated with the respective samples for 10 min at room temperature, 
after which an equal volume of 100 % or 70 % ethanol, for viral RNA or total cellular RNA 
isolation, respectively, was added. The solution was briefly vortexed and pelleted, after which it 
was transferred to a new Eppendorf tube and removed from the BSL-3 laboratory through a 5 % 
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Microchem Plus bath. The RNA was then immediately isolated according to manufacturer’s 
protocol and stored at -20 °C until analysis. 
 
4.3. Rescuing recombinant RVFV expressing LACV NSs mutants 
Seven domains in orthobunyavirus NSs proteins were identified to be conserved throughout the 
genus. We constructed alanine mutants for these conserved domains, in LACV NSs, to 
determine their importance for the different functions of the NSs protein. To be able to 
performed experiments and detect the LACV NSs under viral infection we used a reverse 
genetics system for RVFV developed in our group. Due to the expression of the NSs protein 
from a +1 ORF in the same mRNA as the N protein during authentic LACV infection (see Fig. 
1B), no Flag-tag could be added to the NSs sequence without disturbing the N sequence. RVFV 
expresses the N and NSs from two separate mRNAs, due to ambisense coding of the S segment. 
The NSs protein of RVFV was therefore replaced by the LACV NSs mutants, by conventional 
cloning into a plasmid containing the full-length RVFV S segment. Plasmids containing the 
full-length RVFV segments, transcribed by a RNA polymerase I driven promoter, where then 
transfected into cells to rescue RVFV expressing the different LACV NSs mutants. Plasmids 
encoding for RVFV N and L proteins, under the control of a RNAPII promoters, were co-
transfected to initiate viral transcription and replication. 
 
4.3.1. Conventional cloning of LACV NSs mutants into RVFV S-segment 
In order to construct RVFV expressing LACV NSs, the cloning strategy published in [58] was 
performed where RVFV NSs was replaced by LACV NSs mutants. We used plasmid RVFV 
#40, containing the full-length RVFV S-segment in viral sense, with the NSs ORF replaced by a 
tandem cloning site containing two mirrored AarI sites. Upon digestion with AarI, non-
compatible sticky ends were formed, which were compatible with NcoI and XhoI recognition 
sequences. The 5’ overhangs of the vector were de-phosphorylated with shrimp alkaline 
phosphatase (Fermentas). We amplified the LACV mutants using the KOD Hot Start DNA 
Polymerase (Calbiochem) according to the manufacturer’s instructions with primers RVFV 
#117 and RVFV #118 and plasmids #220 – 226 as templates. The two primers contained a 5’ 
Esp3I site, which upon digestion of the PCR product generated a 5’ NcoI and a 3’ XhoI 
recognition sequence. The vector and PCR products were separated on a 1 % agarose gel in 
TAE buffer at 100 V for 1 h, the bands were stained with 0.5 µg/ml ethidium bromide in ddH2O 
for 20 min and then excised from the gel. The PCR-insert and vector were then gel-purified 
using E.Z.N.A. Gel Extraction Kit (Omega) according to manufacturer’s protocol. A 3:1 ratio, 
of insert to vector, was used to ligate the PCR products into the RVFV S-segment plasmid using 
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T4 DNA ligase (Fermentas) according to the manufacturer’s instructions. The ligated plasmids 
were transformed into competent DH10B bacteria, plated on 100 µg/ml ampicillin LB-agar plats 
(10 g/L peptone, 5 g/L yeast extract, 10 g/L NaCl, 15 g/L agar) and incubated overnight at 37 
°C. The same vector preparation, as used for ligation of the LACV NSs mutants, was re-ligated 
and used as negative control in the transformation of the DH10B cells. One colony from each 
plate was picked and used as both template in a colony PCR and as inoculum for an over-night 
culture in 100 µg/ml ampicillin LB medium (10 g/L peptone, 5 g/L yeast extract, 10 g/L NaCl). 
To assure correct insertion a colony PCR was performed with Taq polymerase (Sigma) 
according to the manufacturer’s instructions with primers RVFV #78 and RVFV #118. As 
template for the PCR the colony on a pipette-tip was dipped into the PCR reaction and then 
transferred to the LB medium, the template amount in the protocol was replaced by ddH2O to 
achieve the correct volume. The PCR reaction was run according to the manufacturer’s 
instruction. The PCR products were separated on a 1 % agarose gel in TAE buffer at 100 V for 
1 h, and the bands stained in 0.5 µg/ml ethidium bromide in ddH2O for 20 min, after which the 
PCR product was visualized using a Gel Doc 2000 (BioRad). The over-night cultures, from the 
same colony that was used in the colony PCR, were isolated using the E.Z.N.A. Plasmid Mini 
Kit I (Omega Bio-Tek) according to the manufacturer’s instructions. To assure that the correct 
mutant had been ligated in the corresponding plasmid the inserts were sequenced by Seqlab 
Sequence Laboratories/Microsynth AG (Göttingen, Germany) in both forward and reverse 
direction using primers RVFV #78 and RVFV #183. 
 
4.3.2. Rescue of recombinant RVFV expressing LACV NSs mutants 
For rescue of RVFV expressing the LACV NSs mutants, a RNA polymerase I/II driven plasmid 
system was used, described in [58]. A 2:1 co-culture of HEK-293 and BHK-21 cells, in 6-well 
plates, were transfected, in duplicates, with a solution containing, in a ratio 1:2, helper plasmids 
#25 (PKR-DN), #28 (RVFV N), #26 (RVFV L) and the full-length plasmids #37 (RVFV vM), 
#36 (RVFV vL) and the respective RVFV S segment containing LACV NSs mutants, #597 – 
603. The transfection was performed under BSL-3 conditions using TransIT-LT1 (Mirus) as 
transfection reagent. After 4 h of incubation at 37 °C (5 % CO2) the cell culture medium was 
exchanged and the cells further incubated for 96 h. The virus-containing supernatants were 
clarified by centrifugation at 1500 rpm for 5 min at room temperature using a Multifuge 4KR 
centrifuge (Heraeus). The cleared supernatants were then used as inoculum to amplify the 
rescued viruses, by two successive propagations on BHK-21 cells, where 72 h, at 37 °C (5 % 
CO2), incubations were used for each propagation. The second passage of the rescued viruses 
was used to grow virus stocks, on Vero 76 cells, as described above in section 7.2.2. The virus 
stocks were titrated by plaque assay as described in section 7.2.3. 
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4.3.3. Validation of the correct LACV NSs mutant inserted in the RVFV 
backbone 
Viral RNA was isolated from virus stocks as described above in section 7.2.4. The isolated viral 
RNA was DNase I-treated, to assure that no rescue plasmid contamination would interfere with 
the interpretation of the result. OneStep RT-PCR (Qiagen) reactions according to the 
manufacturer’s protocol was performed on the viral RNA, amplifying the ORF of RVFV N 
using primers RVFV #97/RVFV #44 or the ORF of NSs using primers RVFV #78/RVFV #183. 
The RT-PCR products were separated on a 1 % agarose gel in TAE (40 mM Tris, 20 mM acetic 
acid, 1 mM EDTA) at 100 V for 1 h followed by staining of the DNA bands with 0.5 µg/ml 
ethidium bromide in ddH2O for 20 min. The PCR products were visualized with a Gel Doc 
2000 (BioRad). To assure that the correct LACV NSs mutant was rescued in the corresponding 
virus the NSs RT-PCR products were sequenced at Seqlab Sequence Laboratories/Microsynth 
AG (Göttingen, Germany) in both the forward and reverse direction using primers RVFV #78 
and RVFV #118. 
 
4.4. Interferon induction assay 
4.4.1. VSV RNA isolation 
As an inducer of the type I IFN system, we used vesicular stomatitis virus (VSV) RNA isolated 
from virus particles. BHK-21 cells (90 % confluent), were infected at a MOI 0.001 of VSV by 
adding an appropriate volume of stock virus directly to the cell culture medium on the cells. The 
cells were then incubated for 72 h at 37 °C (5 % CO2). The cell supernatant, containing released 
viruses, was cleared from cell debris by centrifugation at 1500 rpm for 7 min at 4 °C using a 
Multifuge 1 S-R centrifuge (Heraeus). To precipitate viral particles, the cleared supernatant was 
then mixed with 30% PEG8000 in NTE (10 mM Tris (pH 6.5), 1 mM EDTA, 255 mM NaCl) in 
an Erlenmeyer flask and incubated at 4 °C for 30 min with mild shake. The mixture was 
transferred to a Falcon tube and the viruses pelleted by centrifugation at 6000 rpm for 1 h at 4 
°C in an Avanti J-26 XP (Beckman Coulter). The pellet was then re-suspended in 1.5 mL 
TriFAST (Peqlab) by incubating for 5 min with vortexing every second min. To isolate RNA, 
the solution was transferred to a 15 mL Falcon tube and 300 µl Chloroform added. The tube was 
shaken vigorously, incubated at room temperature for 10 min, and centrifuged at 4600 rpm for 
11 min at 4 °C using a Multifuge 1 S-R centrifuge (Heraeus). This allowed the separation of the 
solution in three phases. The upper phase was transferred to a new 15 ml Falcon tube, 750 µl 
isopropanol and 30 µg glycogen were added and the solution was then incubated at -20 °C for 
16 h. The RNA was then precipitated by centrifugation at 4600 rpm for 33 min at 4 °C using a 
Multifuge 1 S-R centrifuge (Heraeus). The supernatant was discarded and the RNA pellet 
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washed twice with 70 % ethanol. After drying, the pellet of RNA was resuspended in TE buffer 
(10 mM Tris-HCl (pH 8.0), 1 mM EDTA) to a concentration of 250 ng/µl. The VSV RNA 
preparation was aliquoted and stored at -80 °C. 
 
4.4.2. Luciferase reporter gene assay  
To test the LACV NSs mutant’s ability to inhibit induction of innate immunity we used an 
interferon induction assay. A master mix containing the inducible firefly luciferase (under the 
ISG54-promoter, plasmid #77) and the constitutively expressed renilla luciferase (under the 
SV40-promoter, plasmid #48) was prepared in OptiMEM. The master mix was divided and one 
of the LACV NSs mutants (plasmids #220 – 226), LACV NSs wt (plasmid #217) or a control 
plasmid (#219) was added in the presence or not of VSV RNA at a final concentration of 250 
ng/well. The Nanofectin (PAA) transfection reagent was used according to the manufacturer’s 
instructions, and the transfection mixes were incubated at room temperature for 20 min. The 
transfection solutions were then added drop-wise to monolayers of HEK-293 cells (50 % 
confluent) in 12-well plates. The transfection complexes were evenly distributed in the cell 
culture medium by mild shaking on a HS 250 B (IKA Laborteknik) for 5 min at room 
temperature. The cells were then incubated for 4 h at 37 °C (5 % CO2), after which the cell 
culture medium was exchanged and the cells further incubated for 20 h. Firefly and renilla 
luciferase activity was measured with the Dual-Luciferase Reporter Assay System (Promega). 
The cell culture medium was removed and the cells immediately lysed in passive lysis buffer, 
provided in the kit, by direct addition to the well followed by incubation for 20 min with 
vigorous shaking at room temperature. 1/10 of the lysis buffer volume was used for luciferase 
activity measurement in a black 96-well microplate (Greiner Bio-One). The luciferase activity 
was measured in a Centro LB 960 (Berthold Technologies) using the program MiroWin 2000 
(Mikrotek Laborsystem GmbH). For calculations of the respective luciferase activity induction, 
all samples were compared to the control plasmid transfected sample without co-transfection of 
VSV RNA. 
 
4.5. Molecular biology methods 
4.5.1. Western blot for protein detection 
The isolation of protein samples brought out of the BSL-3 has already been described in section 
6.2.3. The same protocol was followed for preparing samples under BSL-2 conditions, however 
only one boiling step of the sample for 10 min at 100 °C was performed. The protein samples 
were loaded onto SDS-PAGE gels, containing a upper stacking gel (4 % 
acrylamide/bisacrylamid (37.5:1 ratio), 125 mM Tris-HCl (pH 6.8), 0.1 % SDS, 0.05 % APS 
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and 1 % TEMED and a lower separation gel containing either 5 % or 15 % 
acrylamide/bisacrylamid (37,5:1 ratio), 375 mM Tris-HCl (pH 8.8), 0,1 % SDS, 0,05 % APS 
and 0,05 % TEMED. The SDS-PAGE gels were run in Mini-Protean Tetra System chambers 
(Biorad) using running buffer (25 mM Tris (pH 8.3), 192 mM glycine, 0.1 % SDS) at a constant 
current of 200 V, allowing the separation of the proteins according to their molecular weight. 
The transfer of proteins to methanol-preactivated Immobilon-P membrane (PVDF, Millipore) 
was performed by wet-blot (5% gels) or semi-dry blotting (15% gels). For wet blot the Criterion 
blotter (Biorad) was used with Towbin buffer (25 mM Tris, 192 mM Glycin, 20 % methanol) 
and was run at 250 mA for 1.5 h. The semidry blotting was performed in Trans-blot SD cell 
(Biorad) using semidry blotting buffer (48 mM Tris, 39 mM Glycine, 0.0375 % SDS, 20 % 
methanol) and was run at 75 mA/gel for 1 h. After blotting, the membranes was washed once in 
TBS buffer (20 mM Tris-HCl (pH 7.6), 137 mM NaCl) followed by blocking in 5 % (w/v) non-
fat milk powder dissolved in TBST (TBS buffer, 0.1 % Tween-20) for 1 h at room temperature 
with mild shaking. Phosphospecific antibodies were diluted in 5 % BSA (w/v) in TBST, while 
all other antibodies were diluted in 1 % (w/v) non-fat milk powder dissolved in TBST. The 
membranes were incubated over-night at 4 °C in the primary antibody solutions. The next day 
the membranes were washed three times in TBST followed by incubation in 5 % (w/v) non-fat 
milk powder dissolved in TBST containing the appropriate peroxidase conjugated secondary 
antibody. Before detection the membranes were washed three times in TBST followed by three 
times in TBS. The proteins bands were visualized in a ChemiDoc XRS+ (Biorad) using 
SuperSignal West Chemiluminescent Substrate (Thermo Scientific). 
 
4.5.2. Immunofluorescence 
To detect the cellular localization of our target proteins indirect immunofluorescence was 
performed. The cell monolayer, grown on coverslips, were infected or transfected and at the end 
of the experimental incubation the cells were washed once in PBS and fixed in 3 % (w/v) 
paraformaldehyde in PBS for 20 min at room temperature. The cells were then washed three 
times with PBS. Permeabilization of the cells was performed by incubating the cells in a 
solution of PBS containing 0.5 % Triton-X 100 for 15 min at room temperature. The cells were 
then washed three times with PBS. To block unspecific primary antibody binding, the cell layer 
was incubated in 1 % FBS in PBS for 20 min at room temperature. The cells were then 
incubated for 1 h with the primary antibodies diluted in 1 % FBS in PBS. The cells where again 
washed three times in PBS, followed by incubation in secondary antibodies, and DAPI, diluted 
in 1% FBS in PBS, for 45 min under dark conditions. Following the staining with secondary 
antibodies the cells were washed three times in PBS and two times with ddH2O before the 
coverslips were mounted on object glasses (Thermo Scientific) using FluorSave (Calbiochem). 
The FluorSave was allowed to polymerize and the mounted coverslips were stored at 4 °C until 
Methods 
36 
analysis. The stained proteins were visualized, and images taken, with an AxioVert 200 M 
microscope coupled to an AxioCam MRm camera (Zeiss). 
 
4.5.3. Real time RT-PCR 
For the detection of cellular mRNA and viral RNA levels, isolated using the RNeasy Kit 
(Qiagen), real time reverse transcription PCR was used. The RNA concentration of each sample 
was measured on a Nanodrop spectrophotometer (Thermo Scientific) and removal of possible 
DNA contamination in the RNA preparation was performed with the gDNA wipeout buffer, 
provided in the QuantiTect Reverse Transcription Kit (Qiagen). Equal amounts of RNA were 
then reverse transcribed using the supplied primer mix, which consists of an oligo-dT and 
random primers. The synthetized cDNA was then used as template for the real time PCR 
reactions with the QuantiTect SYBR Green PCR Kit (Qiagen), or for RVFV L RNA detection 
with the SensiMix II Probe Kit (Bioline). The internal control 18S ribosomal RNA and the 
mRNAs for IFN-β, ISG56 were detected with QuantiTect Primers (Qiagen) while γ-actin-intron 
assay [36], LACV N [160] and RVFV L [17] were detected with indicated published primers. 
Due to the high amount of 18S ribosomal RNA the cDNA was diluted 1:100 for this specific 
gene analysis. The real time PCR reaction and measurement was performed on a StepOne 
System (Applied Biosystems). For relative RNA calculations the ΔΔCt method [92] was used 
with 18S ribosomal RNA as internal control. Two controls for each primer-pair were used; 1) 
ddH2O was used as template in one reaction and 2) a non-reverse transcribed Mock sample 
RNA. A melt curve analysis, at the end of the real time PCR program, was performed to assure 
that the SYBR green signal detected came from one amplicon with the same Tm. 
 
4.6. Statistical analysis 
When statistical analysis was performed, comparing two groups of samples, a two-tailed, 
unpaired t-test was performed using Microsoft Excel. P-values ≤ 0.05 were considered as 
significant, indicated with (*) in figures where statistical analysis were performed. 
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5. Results1 
The major function of the NSs protein of the Bunyaviridae is the inhibition of innate immune 
induction of mammalian hosts [132]. However, the mechanism varies between the genera and 
from virus to virus. As for other members of the Bunyaviridae genus orthobunyaviruses, LACV 
NSs acts on the transcriptional level. Indeed, our group had demonstrated that LACV NSs 
induces the proteasomal-degradation of the largest subunit, RPB1, in transcriptionally 
elongating RNA polymerase II [160]. 
 
5.1. Time course for induction of RPB1 disappearance under 
infection 
5.1.1. Time course of wt LACV induced RPB1 disappearance 
To confirm previous result of LACV NSs induced RPB1 disappearance, and to determine the 
kinetics of RPB1 disappearance in LACV wt-infected cells, time course experiments were 
performed with samples taken 1, 2, 3 and 4 hours post infection (h.p.i.). We also compared with 
the kinetics of RPB1 disappearance in cells treated with either the general transcription inhibitor 
Actinomycin D or the RNAPII specific inhibitor α-amanitin. 
The Western blot result of a representative time course is depicted in Fig. 2. Total RPB1, with 
the IIA (transcriptionally inactive) and the IIO (transcriptionally elongating) forms, and the 
specific markers for transcription initiated (CTDpSer 5) or elongating (CTDpSer 2) RPB1 is 
presented. As no antibody against LACV NSs is available, we monitored the infection by 
detection of the N protein, which is expressed from the same mRNA as the NSs protein (Fig. 
1B). The two viruses displayed different growth kinetics. LACV wt grew faster, with weak N 
protein detection already 1 h.p.i., while LACV ΔNSs grew slightly slower with N protein 
detection 3 h.p.i. (Fig. 2). The growth kinetics for LACV wt correlated with the disappearance 
kinetics for RPB1, with a lack of total RPB1 seen already 1 h.p.i. However, unlike the 
disappearance of RPB1 observed previously for LACV wt, where first the IIO form disappears 
and an increased signal of the area in-between the IIO and IIA form was noted [160], a 
synchronized disappearance of both RPB1 forms was observed (Fig. 2). 
                                                     
1
 The results presented in this thesis have not been published so far in any peer-reviewed scientific journal. However a manuscript is 
under preparation. Not all data produced during the work will be presented. 
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Figure 2. LACV NSs induces RPB1 degradation faster than transcription inhibitors. HuH-
7 cells were Mock -treated, infected with LACV wt or LACV ΔNSs (MOI 10), or treated with 
α-amanitin (10 µg/ml) or Actinomycin D (10 µg/ml). The infection/treatment was allowed to 
progress for the indicated time until samples were taken and analysed by SDS-PAGE and 
Western blot. The figure is representative of at least three independent experiments. 
 
The slight difference in the disappearance pattern for RPB1, between these and previously 
published results [160], might be the difference in cell line (Vero cells in [160] versus Huh7 
cells here) used for the experiments. However, when comparing the disappearance of total 
RPB1 in LACV wt infected cells with total RPB1 in LACV ΔNSs infected cells, the IIO form of 
RPB1 is most affected of the two forms in agreement with published observations [160]. No 
degradation of RPB1 was detected in LACV ΔNSs infected cells. The transcriptionally 
elongating form of RPB1, CTDpSer 2, started to diminish at 3 h.p.i. in wt LACV infected cells 
(Fig. 2). A possible explanation for the slight delay in induction of disappearance between total 
RPB1 and the transcriptionally elongating form in LACV wt infected cells, might be the 
different antibodies used where the phosphor-specific one is more sensitive. The antibody used 
to detect total RPB1 recognizes one epitope on RPB1 while the phosphor-specific antibody has 
up to 52 epitopes it could recognize. The initial disappearance of CTDpSer 2 is in agreement 
with published results, demonstrating that LACV NSs targets the transcriptionally elongating 
form of RPB1. However, unlike the disappearance of total RPB1 and CTDpSer 2, the 
transcriptionally initiated form of RPB1, CTDpSer 5, was observed to increase in LACV wt 
infected cells (Fig. 2). This increased signal for CTDpSer 5 might be an attempt by the cells to 
promote transcription in response to the NSs induced disappearance of the elongating CTDpSer 
2 form of RPB1. A similar, but not as pronounced, increase in transcriptionally initiated RPB1 
was seen for Actinomycin D. The treatment of cells with α-amanitin induced the disappearance 
of total RPB1 3 h after the start of inhibitor treatment, slight delay compared to LACV wt 
infection. Both treatment with α-amanitin and Actinomycin D caused the IIA form of RPB1 to 
disappear initially, followed by the IIO form in α-amanitin treated cells. Actinomycin D 
treatment of cells did not have any effect on the IIO form but slightly increased the CTDpSer 2 
RPB1
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signal. Finally, α-amanitin treatment induced a slight decrease in the CTDpSer 5 form 3 h.p.i., 
but no striking effect was seen on the CTDpSer 2 form (Fig. 2). 
 
5.1.2. Time course of RPB1 disappearance in cells infected with a 
heterologous virus expressing LACV NSs 
To be able to detect LACV NSs expression under viral infection, we took advantage of a 
recombinant Rift Valley Fever virus (RVFV, phlebovirus) expressing the LACV NSs with an N 
terminal 3×Flag-tag [58]. The 3×Flag tag could not be added directly to the NSs in the authentic 
LACV background since the NSs is expressed from a +1 shifted ORF embedded in the N 
protein mRNA (Fig. 1B). The N protein is essential for viral replication and therefore no change 
in the sequence of NSs could be made without disturbing the N sequence. To compare the 
kinetics of RPB1 degradation, and the possible correlation with NSs expression, HuH-7 cells 
were infected with RVFV expressing either 3×Flag-tagged LACV NSs or RVFV NSs. 
Under infection with RVFV expressing LACV NSs, the induction of total RPB1 disappearance 
was detected 3 h.p.i., as a lack of the IIO form of RPB1 (Fig. 3). This is slightly later then for 
LACV wt seen in Fig. 2. However, the expression of the LACV NSs protein correlated with the 
induction of RPB1 disappearance. The RVFV NSs does not induce any disappearance of RPB1. 
However, would we have allowed the infection to progress, the RVFV NSs inhibition of THIIH 
[75, 76, 87] would most likely have caused a RPB1 disappearance as a secondary effect due to 
transcription inhibition, as seen for α-amanitin. 
 
Figure 3. LACV NSs expressed by RVFV induces degradation of RPB1 with similar 
kinetics as the LACV wt. HuH-7 cells were either Mock-treated or infected with RVFV 
expressing either LACV NSs or RVFV NSs (MOI 10) for the indicated times. Samples were 
taken and analysed by SDS-PAGE and Western blot. The image is representative of three 
independent experiments. 
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Interestingly, even though the expression of the two NSs proteins are regulated by the same 
promoter in the RVFV, levels of LACV NSs are much weaker than of RVFV NSs (Fig. 3), most 
likely indicating a lower stability of LACV NSs. A lower stability of LACV NSs compared to 
the NSs protein of another orthobunyavirus Snowshoe hare virus have also been reported [50]. 
The RVFV N protein, used as a control for the infection, displayed similar kinetics and 
expression for the two viruses. 
In summary, LACV NSs induces the disappearance of RPB1 faster than the specific RNAPII 
inhibitor α-amanitin. Furthermore, the induction of RPB1 disappearance correlates with the 
expression of LACV NSs, and LACV NSs is sufficient to degrade RPB1 independently of the 
viral background. 
 
5.2. LACV NSs Pull down assays of Elongin C 
After having identified the mechanism of LACV NSs inhibition of the antiviral type I IFN 
induction, by degradation of RPB1 in transcriptionally elongating RNAPII [160], it was of 
interest to identify host-cell interactors of the LACV NSs protein. Attempts in our group to 
identify NSs interactors had been performed via pull down assays on E3 ligase subunits. The 
reason for these directed attempts was both the requirement of the proteasomal pathway for 
RPB1 degradation during LACV wt infection and the demonstration of an interaction between 
MED8 and Bunyamwera virus NSs [89]. MED8 is part of the Mediator complex, but has also 
been demonstrated to form an ubiquitin E3 ligase [27]. 
The in vitro pull down assays performed in our group to find LACV NSs interactors were based 
on bacterially expressed GST-tagged LACV NSs or a control protein. Our control protein is the 
first 106 amino acids of the MxA protein, which retains no MxA functions, and has 
approximately the same molecular size as the LACV NSs protein. The pull downs attempts 
were carried out by mixing the GST-tagged proteins, immobilized on glutathione-agarose beads, 
with radiolabelled in vitro transcribed/translated interaction candidates. The only reproducibly 
pulled down interactor of LACV NSs was Elongin C (unpublished, see [159]). No interaction 
was seen between LACV NSs and Elongin A or Elongin B. Elongin C was a promising 
interaction candidate since it has been demonstrated to be a subunit in both the Elongin 
complex, that increases RNAPII transcription elongation rates, and as a subunit of several 
cellular and viral ubiquitin E3-ligases, see chapter 4.7. in the introduction. 
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Figure 4. LACV NSs contains a partial BC box motif. Clustal W alignment of LACV NSs 
and the BC boxes from VHL and Elongin A. Only the respective BC boxes and the aligned 
sequence of LACV NSs are shown for clarity, with amino acid residue numbers of the first and 
last residue depicted on-top of the respective sequence. 
 
All known Elongin BC interactor contain a so called BC box motif [(STP)Lxxx(CSA)xxxɸ] 
[93], which is required for interaction with Elongin C. Interestingly, using the Clustal W 
program to align the protein sequence of LACV NSs with the BC boxes from the VHL and 
Elongin A proteins, a partial BC box motif in LACV NSs was identified (Fig. 4). Importantly, 
the crucial leucine residue at position 4, was also present at the correct position in the potential 
LACV NSs BC box (Fig. 4). 
I performed different pull down assays to reproduce the in vitro interaction seen between LACV 
NSs and Elongin C. Flag-tagged LACV NSs and control protein, same as above, were expressed 
by in vitro transcription/translation, plasmid transfection into cells or by the RVFV described in 
section 8.1.2. For the expression of Elongin C or control proteins, different expression systems 
where used. Plasmids encoding Elongin C and the control protein, coupled to Renilla luciferase, 
were used in an in vitro transcription/translation expression system. Another approach was to 
use plasmids encoding Elongin C, control protein or Elongin B, tagged with a HA-tag, to either 
transiently express the different proteins or create stable cell-lines. Different combinations of 
proteins, isolated by the respective expression systems, were combined in pull down 
experiments. However, despite some initially encouraging results, no robust and reproducible 
interaction was detected between LACV NSs and Elongin C. 
 
5.3. Subcellular localization of endogenous proteins during infection 
5.3.1. Subcellular localization of Elongin C under LACV wt infection 
The interaction between LACV NSs and Elongin C might be too weak or transient for 
reproducible detection with pull-down assays. As an alternative, we investigated the subcellular 
localization of Elongin C, and the possible effect LACV NSs might have on it. For this purpose 
HuH-7 cells were mock treated, infected with LACV wt or LACV ΔNSs or treated with the 
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specific RNAPII inhibitor α-amanitin. After completion of the infection, the cells were stained 
against endogenous Elongin C and the LACV N protein. 
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Figure 5. Elongin C is re-localized by LACV NSs from the nucleoli. HuH-7 cells were 
grown on coverslips and either Mock-treated, infected with LACV wt or LACV ΔNSs (MOI 1) 
or treated with α-amanitin (10 µg/ml) for 16 h. The cells were fixed, permeabilized and stained 
against endogenous Elongin C and LACV N protein, the nucleus was counterstained with 
DAPI. Images were taken with a Apotome (Zeiss) at a magnification of ×630. Protein samples 
for SDS-PAGE and Western blot were prepared in parallel to the immunofluorescence samples 
and separated on 5 or 15 % SDS-PAGE gel. The indicated proteins were stained for and 
detected via chemiluminescence in a Chemidoc XRS+ (BioRad). Images and blots are 
representative of at least three independent experiments. 
 
As can be seen for mock treated cells in (Fig. 5), Elongin C primarily localized to patches in the 
nucleus, which most likely corresponds to the nucleoli, with weaker staining of the whole 
nucleus. The microscope setting for taking images was adjusted so as not to overexpose the 
Elongin C in the nucleoli. However, a diffuse and weak staining of Elongin C in the cytoplasm 
was also seen in the microscope (data not shown). To our knowledge this is the first time 
Elongin C has been demonstrated to primarily localize to the nucleoli. This localization was 
unexpected since the nucleolus is the primary site of ribosomal RNA synthesis by RNAPI [56], 
whose transcription Elongin C has not been implicated in. Infection of the cells with LACV wt 
caused a loss of the Elongin C signal, from the nucleoli specifically but also from the complete 
nucleus (Fig. 5, LACV wt). The loss of signal was induced by the NSs protein since infection 
with LACV ΔNSs did not have any effect on Elongin C compared to mock (Fig. 5). To assure 
that the lack of a signal in LACV wt infected cells was not due to a degradation of the protein, 
samples for SDS-PAGE and Western blot was prepared in parallel. We stained against all three 
subunits of the Elongin complex, Elongin A/B/C, but did not detect any change for anyone of 
the subunits (lower part of Fig. 5). Since no degradation of Elongin C was detected, the loss of 
signal in the immunofluorescence was most probably due to a re-localization of Elongin C by 
LACV NSs. To assure that the LACV NSs induced RPB1 disappearance, total RPB1 was 
stained for. This late in infection (16 h.p.i.) barely detectable levels of RPB1 was observed in 
LACV wt infected cells. For cells treated with the specific inhibitor of RNAPII, α-amanitin, we 
also saw a redistribution of Elongin C (Fig. 5). However, unlike cells infected with LACV wt, a 
primarily still nuclear staining for Elongin C was seen. A strong signal for the LACV N was 
seen for both LACV wt and LACV ΔNSs, with a dot-like appearance that are probably viral 
factories for replication and transcription [45]. 
Similar to experiments shown in Fig. 2, time-course experiments for re-localizations of Elongin 
C were performed. However, a firm correlation between onset of RPB1 disappearance and a re-
localization of Elongin C could not be established. 
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5.3.2. Subcellular localization of Elongin A and B under LACV infection 
In Fig. 5, Elongin C was demonstrated to be re-localized by LACV NSs. We then wondered if 
LACV NSs had any effect on the subcellular localization of the two other subunits of the 
Elongin complex, Elongin A and B. To answer this question, similar immunofluorescence 
experiments were performed and HuH-7 cells were stained against Elongin A or Elongin B. In 
Fig. 5 LACV N was used to stain for infection, however due to the same species origin of the 
LACV N and Elongin A/B antibodies, the LACV glycoprotein GC was stained for instead as 
control for infection. As we already demonstrated in Fig. 5 (lower part), none of the Elongin 
subunits were degraded during infection with LACV wt. However, unlike Elongin C, neither 
Elongin A nor Elongin B changed their subcellular localization upon infection with LACV wt 
(Fig. 6). Both Elongin A and B displayed a primarily nuclear staining with a weak cytoplasmic 
signal (Fig. 6). As can be seen in the upper panel, the signal for Elongin A had a dot-like 
appearance in the nucleus. A slightly stronger signal was observed in cells displaying the GC 
signal, compare (LACV wt or LACV ΔNSs infected with Mock, Fig. 6). Upon treatment with α-
amanitin, the signal for Elongin A concentrated in the dot-like structures and less overall 
staining was observed. Elongin B displays a homogenous staining of the nucleus (lower panel, 
Fig. 6), without any changes upon infection or RNAPII inhibitor treatment. A perinuclear 
staining was observed for the GC protein, probably ER/Golgi where viral glycoprotein 
translation and viral budding occur, respectively (Fig. 6). 
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Figure 6. LACV NSs does not affect the subcellular localization of Elongin A or B. HuH-7 
cells were grown on coverslips and either Mock-treated, infected with LACV wt or LACV 
ΔNSs (MOI 1) or treated with α-amanitin (10 µg/ml) for 16 h. The cells were fixed, 
permeabilized and then stained against endogenous Elongin A (upper panel) or Elongin B 
(lower panel) and LACV GC protein, the nucleus was counterstained with DAPI. Images were 
taken with a Apotome (Zeiss) at a magnification of ×630. Images are representative of at least 
three independent experiments. 
 
Thus, LACV NSs specifically re-localizes Elongin C from the nucleoli but has no effect on the 
subcellular localization of Elongin A or B. Differences to α-amanitin indicate that re-
localization is not an unspecific consequence of transcription inhibition by LACV NSs. 
 
5.3.3. LACV wt infection and the nucleolus 
The experiments shown in Fig. 5 and Fig. 6 demonstrated that LACV wt infection caused a re-
localization of Elongin C from the nucleoli, but had no effect on the two other Elongin subunits. 
It was of interest to determine if Elongin C actually localized to the nucleoli and if the re-
localization was specific for Elongin C or a general effect on nucleolar proteins. To study the 
effect on the nucleoli, HuH-7 cells were mock-treated, infected with LACV wt or LACV ΔNSs 
or treated with α-amanitin. Upon completion of the infection the cells were stained for 
endogenous Elongin C and Nucleolin, one of the most abundant nucleolar proteins [148]. 
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As can be seen for the mock sample in Fig. 7, the signals for Elongin C and Nucleolin co-
localized in the nucleoli, further establishing Elongin C as a primarily nucleolar protein. Upon 
infection with LACV wt the signal for Elongin C disappeared, as seen previously, while 
Nucleolin remained in the nucleoli (Fig. 7). The Nucleolin staining got slightly more diffuse in 
appearance and the overall size of the nucleoli decreased in LACV wt infected cells, compared 
to mock. The change in localization of Elongin C and the slight difference in Nucleolin staining 
were induced by the expression of the NSs protein, since the LACV ΔNSs infection displayed a 
staining comparable to the mock sample (Fig. 7). For samples treated with the RNAPII inhibitor 
α-amanitin, the staining for both Elongin C and Nucleolin were disturbed with a diffuse pattern 
of the whole nucleus, and no nucleoli could be seen any more in the nucleus (Fig. 7). 
 
Figure 7. Infection with LACV wt has minimal effects on nucleolar proteins. HuH-7 cells 
were grown on coverslips and either Mock-treated, infected with LACV wt or LACV ΔNSs 
(MOI 1) or treated with α-amanitin (10 µg/ml) for 16 h. The cells were fixed, permeabilized and 
then stained against endogenous Elongin C and Nucleolin, the nucleus was counterstained with 
DAPI. Images were taken with a Apotome (Zeiss) at a magnification of ×630. Images are 
representative of at least three independent experiments. 
 
Thus, LACV NSs has minimal effects on Nucleolin and the nucleoli but specifically re-localizes 
Elongin C from this compartment in the nucleus of infected cells. 
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5.4. Inhibition of nuclear export 
5.4.1. Effect of nuclear export inhibition on Elongin C re-localization during 
LACV wt infection 
The re-localization of Elongin C from the nucleus of infected cells was further studied by 
inhibiting the nuclear export factor CRM1/exportin 1, the major nuclear export factor for 
proteins, with Leptomycin B (LMB). HuH-7 cell were pre-treated for 1 h with LMB, followed 
by either mock treatment, infection with LACV wt or LACV ΔNSs or α-amanitin treatment. 
In Fig. 8A mock and LACV wt infected samples, untreated or LMB-treated, are shown. LMB 
had no effect on the localization of Elongin C in mock (Fig 8A) or LACV ΔNSs/α-amanitin 
treated cells (data not shown). However, CRM1 inhibition in LACV wt infected cells partially 
rescues the Elongin C localization to the nucleoli (Fig. 8A). The rescue of Elongin C in the 
nucleoli was not complete (compare LMB treated mock and LACV wt in Fig. 8A), but was 
reproducibly observed. A slightly weaker signal for LACV N in LMB treated cells was 
observed for both LACV wt and LACV ΔNSs infected cells. However, viral growth for both 
LACV wt and LACV ΔNSs, on cells treated with LMB, were only minimally affected with less 
than 0.5 log difference compared to untreated cells (Fig. 8B). Therefore the difference observed 
between untreated and LMB treated cells, for the Elongin C localization in LACV wt infected 
cells, is due to the export block and not due to an inhibited viral growth. 
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Figure 8. Inhibition of nuclear export via CRM1 partially rescues Elongin C nucleolar 
localization during LACV wt infection. A) HuH-7 cells, grown on coverslips, were either 
untreated or Leptomycin B (16 nM) pre-treated. The cells were then Mock-treated or infected 
with LACV wt (MOI 1) and incubated for 16 h. After fixation and permeabilization the cells 
were stained against Elongin C and LACV N, the nucleus was counterstained with DAPI. 
Images were taken with a Apotome (Zeiss) at a magnification of ×630. B) CV-1 cells, untreated 
or Leptomycin B (16 nM) treated were infected with LACV wt or LACV ΔNSs (MOI 0,01). 24 
h.p.i. samples were taken and titrated by plaque assay. The graph depicts the mean value, with 
standard deviation, for three independent experiments while the images are representatives for 
three independent experiments. 
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5.4.2. Effect of nuclear export inhibition on RPB1 stability during LACV wt 
infection 
In the previous experiment we demonstrate that inhibition of nuclear export via CRM1 
prevented the re-localization of Elongin C from the nucleus in LACV wt infected cell. We 
therefore wanted to see what effect the inhibition of nuclear export might have, under infection 
with LACV wt, on RPB1. For this purpose HuH-7 cells were pre-treated with control or LMB-
containing medium followed by mock, LACV wt or LACV ΔNSs infection, or α-amanitin 
treatment. After removal of the inoculum, medium was added to the cells containing either 
MG132 (proteasomal inhibitor) or LMB alone or the combination of the two, and the cells were 
then incubated for 8 h. Upon completion of the infection, samples were prepared and separated 
on 5 or 15 % SDS-PAGE gels followed by Western blot and staining for the indicated proteins. 
In Fig. 9 the effect of LMB and/or MG132 treatment on RPB1, under infection or α-amanitin 
treatment, is depicted. The proteasomal inhibitor MG132 almost completely rescued RPB1 from 
degradation in LACV wt infected cells, in agreement with previously published results [160]. 
However, in LACV wt infected cells, treatment with LMB did not rescue RPB1 from 
degradation (Fig. 9). In LACV wt infected cells, treated with both MG132 and LMB 
demonstrated a rescue of both total RPB1 and the transcription elongating form (CTDpSer 2), 
slightly better than for the MG132 alone (Fig. 9). 
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Figure 9. Inhibition of nuclear export does not rescue RPB1 from degradation under 
LACV wt infection. HuH-7 cells were pre-treated with control or LMB (16 nM) containing 
medium for 1 h and then Mock-treated, LACV wt or LACV ΔNSs infected (MOI 10) or treated 
with α-amanitin. Upon completion of the infection, medium was added containing either 
MG132 (10 µM) or LMB (16 nM) or the combination of the two. 8 h.p.i. samples were prepared 
and separated on 5 or 15 % SDS-PAGE gels followed by Western blot. The indicated analytes 
were stained for and detected by chemiluminescence in a Chemidoc XRS+ (BioRad). The figure 
is representative of at least three independent experiments. 
The same effect on RPB1 was also seen for the α-amanitin treated cells: MG132 treatment 
rescued total RPB1 and the transcriptionally elongating form, while LMB treatment did not 
inhibit degradation. Also here, the combination of MG132 and LMB demonstrated the 
dominance of the proteasomal inhibitor (Fig. 9). A curious effect of LMB treatment was the 
observed slight decrease in the Elongin C signal (Fig. 9). The treatment of the infected cells 
with MG132 had detrimental effect on the viruses, as can be seen for the LACV N staining (Fig. 
9). Especially LACV ΔNSs was affected with no detection of the N protein in MG132 treated 
cells, but also LACV wt was slightly affected compared to untreated cells. 
Thus, LACV NSs re-localizes Elongin C from the nucleoli to the cytoplasm via CRM1, where 
inhibition of CRM1 dependent export from the nucleus partially rescues the Elongin C signal in 
the nucleoli. However, inhibition of CRM1 has no effect on RPB1 degradation by LACV NSs, 
indicating that the degradation of RPB1 occurs directly in the nucleus. 
 
5.5. Mutants of LACV NSs conserved domains 
5.5.1. Alignment of orthobunyavirus NSs proteins 
In an attempt to map the domain(s) responsible for LACV NSs inhibition of type I IFN 
induction and Elongin C re-localization, our alanine mutants of the LACV NSs were used. 
These mutants, at positions in the NSs protein that is conserved within the orthobunyavirus 
genus, had already been created in the lab (V, Wagner and F, Weber, unpublished), but for 
clarity a brief description of them will be given here. 
The NSs protein sequences from viruses in the orthobunyavirus genus were downloaded from 
the NCBI protein database. A total of 69 NSs sequences were found, of which 3 sequences were 
partial and therefore not used for the alignment. In Fig. 10 the alignment of 22 NSs protein 
sequences, of representative orthobunyaviruses, are shown (an alignment of all 66 NSs 
sequences can be seen in Appendix 1). The alignments were performed with the ClustalW 
program and conserved residues were shaded with the BioEdit program using the BLOSUM62 
matrix. Only residues that are conserved at the respective position, bases on a consensus 
calculation performed by the program, are coloured. 
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Figure 10. Seven conserved domains identified in protein sequence alignment of 
Orthobunyavirus NSs proteins. The 22 NSs protein sequences, from representative 
orthobunyaviruses, were aligned using ClustalW. The resulting alignment was then shaded with 
BioEdit using the BLOSUM62 matrix set to 80 % identity. Depicted is the resulting alignment 
where coloured residues either are completely conserved or share biochemical properties. 
 
As can be appreciated in the alignment in Fig. 10 (and Appendix 1) the NSs proteins are fairly 
similar in sequence for all orthobunyaviruses. Only with the relatively high 80 % similarity 
level could conserved regions be identified. A total of 7 conserved domains were identified. The 
conserved residues at theses domains were mutated to alanine, via site-directed mutagenesis, 
creating 7 LACV NSs mutants termed: L11A, 18to22A, 33to38A, 41to48A, 57to59A, 67to71A 
and 78to87A. As mentioned we lack antibodies to detect the NSs protein, and therefore all 
mutants were N terminally Flag-tagged for detection. 
 
5.5.2. Re-localization of Elongin C by the LACV NSs mutants 
To characterise the LACV NSs mutants’ ability to re-localize Elongin C from the nucleus, 
immunofluorescence experiments, with transfected HuH-7 cells, were performed on samples 
taken 16 h post transfection. 
Transfection of the plasmid expressing our control protein, the N terminal 106 amino acids of 
the MxA protein, resulted in a flag staining of the whole cell (Fig. 11). No change in Elongin C 
localization was seen with the major staining, as before, detected in the nucleoli. The staining 
for Flag-tagged NSs wt resulted in a very weak and barely detectable staining of the nucleus 
(Fig. 11). The reasons for this weak staining might be due to 1) the low stability of the LACV 
NSs protein that has been observed previously (see Fig. 3 and [50]) and/or 2) the use of a 
RNAPII dependent plasmid, which would inhibit the expression due to the NSs protein 
inhibition. 
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Figure 11. All LACV NSs mutants, except L11A, have lost the ability to re-localize Elongin 
C. HuH-7 cells grown on coverslips were transfected with plasmids expressing either a flag-
tagged control protein, LACV NSs wt or the LACV NSs mutants and samples were taken 16 h 
post transfection. After fixation and permeabilization the cells where stained against Elongin C, 
flag and the nucleus was counterstained with DAPI. Images were taken with a Apotome (Zeiss) 
at a magnification of ×630. White arrows indicate cells expressing NSs wt or the respective 
mutant. Images are representative of at least three independent experiments. 
 
However, even though the NSs wt protein was barely detectable, the re-localization of Elongin 
C was readily observed. The LACV NSs mutants displayed marked difference in the Flag-
staining (Fig. 11). The L11A mutant displayed a weak Flag staining of primarily the nucleus, 
similar to that seen for NSs wt. The expression of the remaining mutants was always stronger, 
compared to the NSs wt, and the subcellular localization of them varied from mutant to mutant. 
The 18to22A NSs was seen in the whole cell, 33to38A NSs was primarily nuclear, while the 
41to48A mutant NSs was primarily cytoplasmic (Fig. 11). Mutants 57to59A and 67to71A 
displayed a perinuclear staining that was very prominent in the latter mutant. The most C 
terminal mutant, 78to87A, was seen throughout the cell with no primary localization (Fig. 11). 
The ability of the NSs mutants to re-localize Elongin C also varied, like their respective 
expressions. The L11A was the only mutant that reproducibly re-localized Elongin C from the 
nucleoli (Fig. 11). Mutants 18to22A, 33to38A and 41to48A had entirely lost the ability to re-
localize Elongin C, which was reproducibly observed in the experiments (Fig. 11). The 
remaining three mutants, 57to59A, 67to71A and 78to87A displayed varying effects on Elongin 
C: on the same coverslip either the mutants had an effect, or they did not re-localize Elongin C. 
From these results I conclude that most domains of the LACV NSs protein, except the 
conserved leucine at position 11, are needed for the re-localization of Elongin C. 
 
5.5.3. Inhibition of type I interferon induction by the LACV NSs mutants 
To study the effect of the LACV NSs mutants on the type I IFN induction I employed a 
transfection-based system. Plasmids expressing the Firefly luciferase, under the control of the 
ISG54-promoter (a type I IFN induction gene [110]), and the constitutively expressed Renilla 
luciferase, under the control of the SV40-promoter, was transfected into HEK-293 cells together 
with Flag-tagged control, LACV NSs wt or LACV NSs mutants. Two wells per plasmid 
expressing a Flag-tagged protein were transfected, where one well was co-transfected with a 
inducer RNA (VSV-RNA) to initiate a type I IFN induction. Following 24 h incubation, the 
luciferase activities were measured and compared to control plasmid transfected sample. 
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Figure 12. All LACV NSs mutants, except L11A, have lost the ability to inhibit type I IFN 
induction. HEK-293 cells were transfected with plasmids expressing Firefly luciferase, under 
control of the ISG54-promoter, and Renilla luciferase, under control of the SV40-promoter, and 
the indicated Flag-tagged proteins. To half of the samples was an inducer RNA co-transfected to 
initiate a type I IFN induction. 24 h post transfection the cells were lysed and the luciferase 
activities measured. A) The fold Firefly luciferase activity compared to the non-induced CTRL 
sample. B) The percentage of Renilla luciferase activity compared to non-induced CTRL 
sample. C) Western blots for Flag-tagged constructs and loading control. The graphs depict the 
mean fold induction (A) or mean percentage (B), with standard deviation, of 3 independent 
experiments while the pictures in (C) are representative of at least three independent 
experiments. 
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The results for the firefly luciferase activity, expressed under the control of the ISG54-promoter, 
are depicted in Fig. 12A. The transfection of the plasmids had minimal, if any, effect on the 
induction of the ISG54-promoter in the absence of inducer RNA. Co-transfection of the inducer 
RNA together with the control plasmid, displayed a ~18-fold induction of the ISG54-promoter 
activity. The same co-transfection of inducer RNA and LACV NSs wt displayed no induction of 
the ISG54-promoter activity, reflecting the ability of LACV NSs to inhibit the type I IFN 
induction. As can be seen in the Fig. 12A, all NSs mutants, except L11A and partially the 
33to38A, had lost the ability to inhibit ISG54-promoter activity. While the L11A mutant 
inhibited to the same extent as LACV NSs wt, the 33to38A mutant displayed a partial 
inhibition. The remaining 5 mutants did not display any inhibition of the ISG54 promoter (Fig. 
12A). 
The use of the constitutively active Renilla luciferase expressing plasmid, under the control of 
the SV40-promoter, is generally used as a transfection control. However, for these experiments 
the constitutively-expressed Renilla luciferase activity was used as a read-out of the inhibition 
of general RNAPII transcription, by the LACV NSs mutants. In Fig 12B the percentage of 
Renilla luciferase activity for all samples, compared to the activity measured for the CTRL 
plasmid transfected and non-induced sample set to 100 %, are presented. The co-transfection of 
inducer RNA, to any sample, reduced the Renilla activity, most probably indicating type I IFN 
induction seen in Fig. 12A. The expression of the NSs wt protein reduced the Renilla activity by 
80 %, compared to control protein transfection. The NSs mutants all retained the ability to 
inhibit general transcription, though with different strengths of inhibition (Fig. 12B). Attempts 
were also made to detect RPB1 degradation by Western blot, by ectopic expression of LACV 
NSs wt or the mutants. However, no degradation was detected (data not shown), even for 
LACV NSs wt, indicating that transient transfection of plasmids encoding for LACV NSs wt or 
mutants was not efficient enough to induce degradation. 
In Fig. 12C, a representative Western blot result for the expression control of the Flag-tagged 
constructs are shown. In un-induced cells the control protein, ~15 kDa, was highly expressed 
while the NSs wt, ~10 kDa, had a much lower expression. All the NSs mutants were detected in 
samples where no inducer RNA had been included, with L11A/33to38A/78to87A having a 
weaker expression, 18to22A/57to59A/67to71A being expressed to the same extent as NSs wt 
and the 41to48A mutant being highly expressed (Fig. 12C). When inducer RNA was co-
transfected the signal for the flag proteins decreased, for NSs wt and the L11A mutant the 
signals were hardly detectable (Fig. 12C). 
Thus, these results point towards two different mechanisms of transcription inhibition by LACV 
NSs. One being an inhibition of general transcription, retained by all LACV NSs mutants, and a 
second inhibition of ISG54-promoter activity where only the L11A mutant, and partially the 
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33to38A mutant, are still functional. The inhibition of type I IFN induction partially correlates 
with the re-localized Elongin C. However, the inhibition of the SV40-promoter activity by 
ectopic expression of LACV NSs wt and the L11A mutant, points to a possible yet un-known 
inhibition mechanism, most probably coupled to the RNAPII degradation observed in infected 
cells. 
 
5.6. Recombinant RVFV expressing LACV NSs mutants 
5.6.1. Rescuing RVFV expressing the LACV NSs mutants 
The above described results for the LACV NSs mutants were all performed by ectopic 
expression of the different LACV NSs mutants. This does not reflect a viral infection, where the 
expression of the NSs is governed by the virus. 
As already mentioned, we had constructed a recombinant RVFV where the NSs ORF had been 
replaced by the LACV NSs wt ORF (Fig. 13). We therefore employed the reverse genetics 
system established in our group [58] for rescuing RVFV expressing the LACV NSs mutants. 
Briefly, the LACV NSs mutants were amplified via PCR, using plasmids 220 – 226 as template, 
and inserted into the full-length RVFV S-segment, via a tandem cloning site at the position of 
the NSs ORF, by conventional cloning. The plasmids were transformed into bacteria and 
colonize were used for colony PCR and to grow stocks of the plasmids. The colony PCR 
demonstrated that the right sized and orientation of the inserts were present in all the rescued 
plasmids (data not shown). After isolation of the respective plasmid, the inserts were sequenced 
and found to be in the correct plasmid and no extra mutations were detected (data not shown). 
 
Figure 13. The S segment coding strategy for orthobunyaviruses and phleboviruses. 
Depicted in the figure is the difference in coding strategies between the two Bunyaviridae 
genera orthobunyavirus (LACV) and phlebovirus (RVFV). In A) the LACV S segment with the 
+1 ORF of NSs compared to the N ORF is shown while B) depicts the ambisense coding 
strategy for the S segment of RVFV. In C) the S segment for recombinant RVFV, were the 
LACV NSs ORF has replaced the RVFV NSs ORF, is depicted. 
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To rescue the different viruses, plasmids containing full-length RVFV L, M and S (with the 
different LACV NSs mutants) segments and helper plasmids were transfected into HEK-
293/BHK cells, in co-culture. The cells were incubated for 5 days, followed by two virus 
amplification passaging’s on BHK cells, 3 day incubation/passage. The final passage was used 
to grow stocks of the viruses. All viruses were successfully rescued but the stock titers varied. 
Table 17 gives an overview of the cloning and rescue of the RVFV expressing the LACV NSs 
mutants. Despite 3 attempts to grow virus stocks, the RFVF LACV NSs 67to71A virus did not 
grow to titers that were high enough, and was therefore excluded from further experiments. 
 
Table 17. Overview of the rescue of RVFV expressing the LACV NSs mutants. 
Mutant Cloned & Sequenced Rescued Titer (PFU/ml) 
RVFV LACV NSs L11A   5.9×106 
RVFV LACV NSs 18to22A   6.5×107 
RVFV LACV NSs 33to38A   7.2×107 
RVFV LACV NSs 41to48A   3.8×106 
RVFV LACV NSs 57to59A   4.0×106 
RVFV LACV NSs 67to71A   2.9×105 
RVFV LACV NSs 78to87A   2.8×107 
 
5.6.2. Effect of the RVFV LACV NSs mutants on RPB1 stability 
To characterize the effect of the virally expressed LACV NSs mutants, I tested their ability to 
induce degradation of RPB1. For these experiments we used the two cell lines Huh7 cells, used 
in previous experiments, and A549 cells since they have a strong type I IFN induction and have 
been used previously to study recombinant RVFV [58]. The cells were either mock-treated or 
infected with RVFV expressing our control protein instead of the NSs, RVFV wt, RVFV LACV 
NSs wt or the mutants. At 6 h.p.i. protein samples were collected and separated on 5 or 15% 
SDS-PAGE gels followed by Western blotting. 
In Fig. 14A, the Western blot results for the two cell lines infected with the different viruses are 
presented. As expected and depicted earlier (Fig. 3), the RVFV expressing LACV NSs wt 
induced a degradation of RPB1, seen for total RPB1 and for both transcriptionally initiated 
(CTDpSer 5) and elongating (CTDpSer 2) forms in both cell lines (Fig. 14A). The ability of the 
LACV NSs mutants to induce the degradation of total RPB1 were partially retained by all 
mutants, see total RPB1 in Fig. 14A. The strength of the degradation of total RPB1, by the 
LACV NSs mutants, varied between the mutants and also for the same mutant in the two cell 
lines e.g. compare LACV NSs 41to48A in A549 and Huh7 cells (Fig. 14A). Due to this 
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variance in degradation induction the Image lab software was used to quantify the IIO and IIA 
bands and the area in-between, the CTDpSer 2 and the CTDpSer 5 bands. The quantification 
values were normalized to β-tubulin and compared to Mock-treated cells. The LACV NSs 
mutants all retained the ability to degrade RPB1, but to different degrees (Fig. 14B top). 
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Figure 14. Most of the virally expressed LACV NSs mutants induce the degradation of 
RPB1. A549 or Huh7 cells were mock-treated or infected with the indicated viruses. At 6 h.p.i. 
protein samples were taken and used for SDS-PAGE and Western blot. A) Representative result 
for Western blot for the two different cell lines. B) Graphs depicting fold change of total RPB1 
staining (top), CTDpSer 2 staining (middle) and CTDpSer 5 staining (bottom) for pooled 
quantification values from A549 and Huh7 cells. The graphs show the relative amount of 
staining for each sample, normalized to β-tubulin and compared to mock treated sample. The 
infection with the RVFV expressing LACV NSs mutants were performed once for each 
indicated cell line. 
 
However, the results have to be taken cautiously since the degradation induced by LACV NSs 
wt is not that striking in either of the two experiments (Fig. 14A) which is also observable in the 
quantification (Fig. 14B, top). Unlike the retained ability for all mutants, except L11A, to 
induce degradation of RPB1, neither of the mutants induced the disappearance of 
transcriptionally initiated or elongating RPB1 (Fig. 14A and B, middle and bottom). The Flag 
staining for the expression of the tagged proteins displays a strong signal for the control protein 
and RVFV NSs wt in both cell lines. The LACV NSs wt and mutants were so weakly expressed 
that no signals were seen in A549 cells while a weak staining was observed in Huh7 cells, 
except for the 78to87A mutant that was strongly expressed (Fig. 14A). The RVFV N protein 
staining of samples from A549 cells showed infection for all viruses, but with different 
strengths. The N staining were comparable for the majority of the viruses, but RVFV LACV 
NSs mutants 41to48A and 78to87A showed stronger staining while L11A and 33to38A had 
weaker staining. In Huh7 cells the RVFV N staining were more comparable between the 
different viruses with only weak staining in LACV NSs wt infected samples and strong staining 
in 57to59A and 78to87A infected samples (Fig. 14A). The Elongin C staining were comparable 
between the samples from A549 cells, except for mock and the 33to38A mutant infected 
samples with markedly less Elongin C staining. Samples from Huh7 cells showed either a 
strong signal for all samples or no Elongin C at all (Fig. 14A). However, no pattern in the 
difference could be determined. 
 
5.6.3. Effect of the RVFV LACV NSs mutants on host cell transcription 
Due to the retained ability of most LACV NSs mutants, expressed by RVFV, to induce the 
degradation of RPB1 the effect on host cell transcription under infection was studied. Similar 
infections of A549 cells, as performed for experiments depicted in Fig. 14, were done and 6 
h.p.i. total cellular RNA was isolated and used as template for RT real-time PCR. 
Unlike the retained ability of most LACV NSs mutants in inducing degradation of total RPB1, 
all RVFV expressed LACV NSs mutants had lost the ability to inhibit innate immune induction, 
seen both as the induction of IFN-β and ISG56 mRNAs (Fig. 15A and B). However, all LACV 
Results 
60 
NSs mutants, except the 78to87A mutant, retained some ability to inhibit general transcription, 
seen by the γ-actin intron assay (Fig. 15C), which measures ongoing transcription [160]. All the 
RVFV LACV NSs mutant viruses presented with a lower amount of RVFV L RNA, compared 
to the LACV NSs wt (Fig. 15D), which probably is due to the increased type I IFN induction. 
 
Figure 15. All virally expressed LACV NSs mutants have lost the ability to inhibit type I 
IFN induction, but partially retain general transcription inhibition. A549 cells were treated 
as in Fig. 14. At 6 h.p.i. total cellular RNA was isolated and used as template for cDNA 
synthesis and real time PCR. The graphs depict the fold induction compared to mock-treated 
cells of A) IFN-β mRNA, B) ISG56 mRNA, C) γ-actin intron assay and D) RVFV L RNA 
levels. IFN-β mRNA, ISG56 mRNA and γ-actin intron assay were detected by SYBR Green 
while RVFV L RNA was detected via TaqMan. The graphs show the result from one 
experiment. 
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To sum up the results for the LACV NSs mutants, all mutants induce the degradation of RPB1, 
with different efficiencies, compared to mock-treated cells (Fig. 14A), which correlates with the 
partial inhibition of general host cell transcription (Fig 15C), except for mutant 78to87A. The 
inhibition of general host cell transcription was also seen for all ectopically expressed LACV 
NSs mutants (Fig. 12B). The loss of type I IFN induction inhibition for all LACV NSs mutants 
was observed irrespective of expression system, except for ectopically expressed L11A (Fig. 
12A and Fig. 15A & B). A weak pattern could be distinguished where loss of inhibition of the 
type I IFN induction seems to correlate with the inability to suppress transcriptionally active 
RPB1. The degradation of RPB1 on the other hand, correlated with inhibition of general 
transcription. However, these experiments need to be repeated and the difference for the two 
LACV NSs mutants, L11A in type I IFN induction inhibition and 78to87A in general 
transcription inhibition, requires further clarification. 
 
5.7. siRNA mediated knockdown of the Elongin complex subunits 
5.7.1. RPB1 stability in Elongin subunit knockdown cells 
In Fig. 5 we showed that LACV NSs re-localizes Elongin C from the nucleus, specifically from 
the nucleoli (Fig. 7), but had no effect on the two other subunits of the Elongin complex, 
Elongin A and B (Fig. 6). To further study the connection between LACV NSs and Elongin C, 
we performed individual knockdowns of the Elongin complex subunits using siRNAs. A549 
cells were again chosen for these experiments due to their robust type I IFN induction upon 
infection. The knockdowns were performed twice with 72h and 24h incubations in-between 
each siRNA transfection. The cells were mock-treated or infected with LACV wt or LACV 
ΔNSs (MOI 10) and then incubated for 16 h. Protein samples for SDS-PAGE and Western blot 
were prepared and run on 5 or 15 % gels. 
All knockdowns of the Elongin subunits were successful: no bands for Elongin B or C were 
seen, while the Elongin A knockdown at least diminished the amount of the protein (Fig. 16A). 
Of note, the knockdown of Elongin C resulted in the disappearance of Elongin B, and vice 
versa, which was reproducibly observed. Since Elongin B and Elongin C forms a complex 
(Elongin B/C), the lack of stability if one of the components is missing is not unexpected. 
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Figure 16. Knockdown of Elongin C partially rescues RPB1 from degradation in LACV 
wt-infected cells. A549 cells were either treated with control or siRNAs against the indicated 
subunits of the Elongin complex. The knockdown was performed twice over a 96 h time period 
after which the cells were either mock, LACV wt or LACV ΔNSs (MOI 10) infected and 
incubated for 16 h. The protein samples were run on either 5 or 15 % SDS-PAGE gel followed 
by Western blot and staining against the indicated analytes. A) representative result for protein 
staining’s. B) quantification of the total RPB1 staining (top), CTDpSer 2 staining (middle) and 
CTDpSer 5 staining (bottom). The graphs shows the relative amount of staining for each 
sample, normalized to β-tubulin and compared to mock control siRNA treated sample. The 
graphs depict the mean values, with standard deviations, for at least three independent 
experiments, (*) P≤0.05. Images are representative for at least three independent experiments. 
 
The knockdown of any Elongin subunit had little effect on the RPB1 stability in mock-treated 
cells (see total RPB1, Fig. 16A). The slightly stronger signal for total RPB1 in Elongin B 
knockdown cells were not reproducibly observed. However, infection with LACV wt 
demonstrated a weak, but reproducible rescue of total RPB1 when any of the Elongin subunits 
was knocked down (Fig. 16A). As seen previously, LACV ΔNSs infection did not induce 
degradation of RBP1. To better discern an effect by the Elongin knockdowns we quantified total 
RPB1, the IIA and IIO forms and the area in-between, the CTDpSer 2 and CTDpSer 5 bands and 
the loading control β-tubulin, using the Image Lab software (BioRad). The relative values for 
the different staining’s were then normalized to the loading control value, and compared to the 
control siRNA-treated and mock-infected sample (Fig. 16B). A Students t-test demonstrated 
that, only in Elongin C knockdown cells was the rescue of total RPB1 statistically significant (P 
≤ 0.05). As can be seen in both the staining for total RPB1 (Fig. 16A) and in the quantification 
graph for total RPB1 (Fig. 16B upper), a partial rescue was also seen for the knockdowns of 
Elongin A and B. In contrast to total RPB1, the transcriptionally active RPB1, CTDpSer 2 and 
5, were not rescued in any of the knock down cells infected with LACV wt (Fig. 16A). The 
knockdown of Elongin B or C slightly weakened the signal for transcriptionally elongating 
RPB1 (CTDpSer 2) (Fig. 16A and B, middle) for all virally infected samples. Transcription 
initiated and elongating RPB1, in the Elongin A knockdown cells, were comparable to control 
siRNA-treated cells. The infection was monitored by staining for LACV N protein, which 
showed comparable infections between both LACV wt and LACV ΔNSs, and between the 
different knockdown cells (Fig 16A). However, in growth experiments, on Elongin subunit 
knockdown A549 cells, both LACV wt and LACV ΔNSs displayed reduced titers, by ~1 log, in 
Elongin A and C knockdown cells 24 h.p.i. (Fig. 17). 
Thus, the knockdown of especially Elongin C partially rescues RPB1 from degradation by 
LACV wt, indicating that the interaction between LACV NSs and Elongin C plays a role in 
RPB1 degradation. 
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Figure 17. siRNA mediated knockdown of Elongin A and C, partially decreases LACV wt 
and LACV ΔNSs growth. A549 cells were either treated with control or siRNAs against the 
indicated subunits of the Elongin complex. The knockdown was performed twice over a 96 h 
time period after which the cells were infected with either LACV wt or LACV ΔNSs (MOI 
0,01). 24 h.p.i. samples were taken and titrated by plaque assay. The graph depicts the mean 
value, with standard deviation, for three independent experiments. 
 
5.7.2. Host cell transcription in Elongin subunit knockdown cells 
Due to the partial rescue of RPB1 from degradation in Elongin C knockdown cells, it was of 
interest to determine the effect on the type I IFN induction in Elongin subunit knockdown cells 
under infection. The same knockdown procedure and infections, as performed for the Western 
blot experiments in Fig. 16 were repeated and the induction measured. Total cellular RNA was 
isolated and used as template for RT real-time PCR. 
As can be seen in Fig. 18A – C, the knockdown of any one of the Elongin complex subunits, 
caused a partial rescue of both the type I IFN induction and general transcription in LACV wt 
infected cells. However, only in the Elongin C knockdown cells were the rescue of IFN-β 
mRNA transcription induction statistically significant. The same effect was observed also for 
the ISG56 mRNA transcription, but not to statistical significance. There was no difference in 
the induction of IFN-β and ISG56 mRNA expression in response to LACV ΔNSs infection (Fig. 
18A & B). A general increase of transcription in LACV wt infected cells was also seen in the γ-
actin intron assay, which measures ongoing transcription [160], however, not to statistical 
significant levels. In addition to this increased transcription in LACV wt infected cells, an 
increase in general transcription for all the samples from the Elongin C knockdown cell was 
observed (Fig. 18C). The same effect, but weaker, was seen also for the Elongin B knockdown 
samples. Both LACV wt and LACV ΔNSs displayed similar viral N RNA levels for all samples. 
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Figure 18. Partial rescue of type I IFN induction by knockdown of Elongin C in LACV wt-
infected cells. The same knockdown procedure was performed as described in Fig. 16. Total 
cellular RNA was isolated and used for RT real time PCR. The graphs show the mean fold 
induction, with standard deviation, over Mock control siRNA treated cells from three 
independent experiments. A) IFN-β mRNA, B) ISG56 mRNA, C) γ-actin intron assay and D) 
LACV N RNA. (*) P≤0.05. 
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The partial rescue of RPB1 from degradation, in Elongin C depleted and LACV wt infected 
cells (Fig. 16A), correlated with an increased transcription of primarily IFN-β mRNA (Fig. 
18A), but also ISG56 mRNA and general transcription. This indicates that the interaction 
between LACV NSs and Elongin C contributes to the inhibition of the type I IFN induction in 
infected cells. However, the induction levels are not comparable to those seen for LACV ΔNSs-
infected cells, indicating that other mechanisms of inhibition by NSs exist. 
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6. Discussion 
 
During wild type orthobunyavirus infection of mammalian cells, the main function of the NSs 
protein is the inhibition of type I IFN induction [20, 43, 165]. This phenotype of the NSs protein 
has been demonstrated for BUNV, SBV and LACV, and is due to the inhibition of transcription 
elongation RNAPII [13, 152, 160]. In attempts to identify host cell interactors of LACV NSs, 
our group identified Elongin C. Here, I have demonstrated that LACV NSs sequesters Elongin 
C from its nucleolar localization (Fig. 5), and re-localizes it to the cytoplasm via the nuclear 
export factor CRM1 (Fig. 8). While the NSs re-localized Elongin C, it had no effect on the 
localization of Elongin A or B (Fig. 6) and only minimal effects on the nucleolar protein 
Nucleolin (Fig. 7). Unlike the partial rescue of Elongin C in the nucleoli in CRM1 inhibitor 
treated cells, no rescue of RPB1 from degradation was seen in Western blot (Fig. 8). However, 
in siRNA mediated Elongin C knockdown experiments, a partial rescue of RPB1 was observed 
(Fig. 16). Concomitantly with the RPB1 rescue in Western blot, a partial rescue of type I IFN 
induction was seen in LACV wt infected cells lacking Elongin C (Fig. 18). Altogether, the 
results presented in this thesis give further support for the main function of the orthobunyavirus 
NSs in inhibiting the type I IFN induction during infection of mammalian cells, pointing 
towards an involvement of Elongin C. 
 
Table 18. Summary of the results for the loss-of-function studies performed with the 
LACV NSs mutants. 
LACV NSs Wild typ L11A 18to22A 33to38A 41to48A 57to59A 67to71A 78to87A 
P
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Subcellular 
localization 
N N C/N N C C/N C C/N 
Elongin C 
re-localization 
++ ++ - - - - - - (-) (-) (-) 
Inhibition of type 
I IFN response  
++ ++ - - -/+ - - - - - - - - 
Inhibition of host 
cell transcription 
++ + + ++ ++ + + + 
V
ir
a
l 
ex
p
re
ss
io
n
 
RPB1 
disappearance 
++ -/+ + + + + n.a. + 
Inhibition of type 
I IFN response 
++ - - - - - - - - - - n.a. - - 
Inhibition of host 
cell transcription  
++ + + + + + n.a. - - 
N: nuclear, C: cytoplasmic, ++: retains function, +: decreased function, -: loss of function, - -: severe loss of function, in parenthesis 
(): not reproducibly seen, n.a.: not applicable. 
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In attempts to map the functional domains of LACV NSs, via loss-of-function mutants 
generated at domains of high sequence conservation, I was able to differentiate between 
inhibition of type I IFN induction and inhibition of general host cell transcription. An overview 
of the results for the LACV NSs mutants is presented in Table 18. By ectopic expression all 
mutants, except L11A, had reproducibly lost the ability to inhibit type I IFN induction (Fig. 
12A) while all mutants retained the ability to inhibit general transcription (Fig. 12B). The loss 
of type I IFN inhibition roughly correlated with the loss of Elongin C re-localization (compare 
Fig. 12A with Fig. 11). However, the most C-terminal mutants: 57to59A, 67to71A and 
78to87A, will require further experiments to determine their ability to re-localize Elongin C. 
Similar to the results seen for the ectopically expressed LACV NSs mutants, all virally 
expressed mutants had lost the ability to inhibit type I IFN induction (Fig. 15A and B). In 
addition, most of the virally expressed LACV NSs mutants, except 78to87A, partially inhibited 
general host cell transcription (Fig. 15C). The inhibition of general transcription by the virally 
expressed LACV mutants correlated partially with the ability to induce RPB1 degradation 
(compare Fig. 14B top with Fig. 15C). On the other hand, the lack of type I IFN inhibition 
partially correlated with the lack of inhibiting transcriptionally active RPB1 (compare Fig. 15A 
& B with Fig. 14A and B middle). Unfortunately, attempts to determine the intracellular 
localization of Elongin C in cells infected with recombinant RVFV’es expressing LACV NSs 
mutants failed, most probably because the fixation protocol for BSL-3 samples impaired the 
epitope recognition by the Elongin C antibody. Additional experiments are still needed for 
statistical evaluations of the virally expressed LACV NSs mutants, and to try and clarify the 
function of the two mutants, L11A and 78to87A, that displayed differences depending on the 
expression system. 
In summary, LACV NSs might inhibit general transcription by inducing the degradation of 
RPB1 while type I IFN induction is inhibited by decreasing transcriptionally elongating 
RNAPII (primarily CTDpSer 2), possibly via the re-localization of Elongin C. To my 
knowledge, this is the first time a differentiation between inhibition of type I IFN and general 
host cell transcription has been demonstrated for an orthobunyavirus NSs protein. Further 
experiments are needed to determine the different mechanisms. 
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6.1. LACV NSs transcription inhibition compared to other 
Bunyaviridae NSs proteins 
The NSs proteins of the orthobunyaviruses LACV, BUNV and SBV all inhibit RNAPII-
dependent transcription [13, 152, 160]. The BUNV NSs was demonstrated to interact with the 
Mediator subunit MED8 in vitro [89], while our group observed the reproducible in vitro pull 
down between bacterially expressed LACV NSs and in vitro transcribed/translated Elongin C, 
but not MED8 [159]. The Mediator complex is essential and has been determined to be involved 
in both assembly of the RNAPII preinitiation complex, and in transferring signals from 
transcription factors to RNAPII. MED8 is part of the head region and has a function in 
preinitiation complex assembly and as a positive regulator of RNAPII transcription [33]. MED8 
can also form a ubiquitin E3 ligase consisting of Elongin B/C, Cullin 2 and Rbx1 [27], however 
the target(s) for this E3 ligase was never identified. The orthobunyavirus NSs proteins might 
converge on a small set of proteins, which can interact with each other. The BUNV NSs 
interaction with MED8 may prevent its function in promoting RNAPII transcription, while 
LACV NSs interacts with Elongin C. 
The NSs of RVFV (genus: phlebovirus) indirectly inhibits RNAPII transcription, by degrading 
the p62 subunit, and sequestering the p44 subunit, of the general transcription factor THIIH [75, 
76, 87]. The lack of a functional THIIH will cause RNAPII to stall at the promoter, eventually 
leading to pre-mature transcription termination. Since THIIH is a general transcription factor 
needed for all RNAPII transcription, the lack of it in RVFV infected cells causes a severe 
inhibition in transcription but has no direct effect, unlike LACV NSs, on RPB1 in RNAPII, 
although some most likely secondary late effects are visible (see Fig. 3, total RPB1 RVFV 4 
h.p.i.). RVFV NSs promotes the proteasomal-degradation of p62 by assembling a ubiquitin E3 
ligase containing the Skp1 protein [75]. Skp1 and Elongin C have been demonstrated to share 
both similar amino acid sequences and three-dimensional structure [172]. Both proteins, Skp1 
and Elongin C, also fulfil the same function in assembly of ubiquitin E3-ligases, where both 
function as adaptors, recruiting Cullin 2/Rbx1 or Cullin 1/Rbx2, respectively [172]. 
 
6.2. Is LACV NSs-induced RPB1 degradation a primary or 
secondary effect? 
The LACV wt induced proteasomal degradation of RPB1 in transcriptionally active RNAPII is 
very rapid, starting between 1 to 3 h.p.i. depending on the viral expression (Fig. 2 and Fig. 3) 
but is completely rescued in proteasome inhibitor treated cells (Fig. 9 and [160]). RPB1 is stable 
for 6 h in translation inhibited cells [4] while in transcription elongation inhibited cells, RPB1 
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degradation was detected first after 12 h of treatment [13]. The rapid induction of RPB1 
degradation by the proteasome, in LACV wt infected cells, indicates that NSs has a direct effect 
on RPB1 stability and not a secondary effect due to transcription/translation inhibition. 
 
6.3. Difference in RPB1 degradation kinetics between authentic and 
heterologous viral LACV NSs expression 
As demonstrated in Fig. 2 and Fig. 3, the disappearance kinetics of the RPB1 signal in Western 
blot, for LACV wt and RVFV expressing LACV NSs, is slightly different. Using the same MOI 
and the same cell-type, LACV wt induced RPB1 degradation already 1 h.p.i. while the same 
degradation started 3 h.p.i. in RVFV LACV NSs infected cells. This dissimilarity might be due 
to the difference in receptor usage between LACV and RVFV, or the difference in coding 
strategy between the two S segments. LACV NSs is translated from a +1 ORF embedded in the 
mRNA of the N protein while the RVFV NSs is translated from its own mRNA (Fig. 13). Due 
to the phlebovirus S segment ambisense coding strategy, the NSs mRNA is transcribed from the 
viral anti-genome, which necessitates both primary transcription and one round of replication 
before NSs mRNA is synthesised. LACV NSs on the other hand is translated directly after 
primary transcription, from the N mRNA, which might give a slightly faster expression kinetics 
and therefore also a faster kinetic in inducing RPB1 degradation. 
 
6.4. RPB1 phosphorylation dynamics in infected cells 
A band for total RPB1 with a slightly higher mobility, just under the IIO band, can be seen early 
in infection for LACV wt (Fig. 2). A similar band is seen in herpes simplex virus 1 (HSV-1) 
infected cells, called the III band, that represents RPB1 primarily phosphorylated on CTD serine 
5 that is needed for viral transcription [47]. In both LACV wt and HSV-1 infected cells RPB1 
CTDpSer 2 (the transcriptionally elongating form) is targeted by viral proteins. In LACV wt-
infected cells, the NSs rapidly induces the disappearance of the RPB1 CTDpSer 2 form while it 
has less effects on CTDpSer 5 RPB1 (transcriptionally initiated form), which is detected in Fig. 
2 as the appearance of the “III” band. However, unlike HSV-1, LACV wt does not need RNAPII 
for its own transcription. The appearance of the “III” form of RPB1, early in LACV wt 
infection, is a phenotype of the NSs induced degradation of transcriptionally elongating RPB1, 
and not a form of RNAPII transcribing viral genes. In agreement with this, the staining for 
CTDpSer 5 in LACV wt infected cells is much stronger in Fig. 2. A slight increase can also be 
seen for α-amanitin or Actinomycin D treated cells. The increase in CTDpSer 5 modification in 
these cells might be an attempt by the cells to compensate for the RNAPII transcription 
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elongation block. Since the CTDpSer 5 is a prerequisite for the serine 2 modification, an 
increase by the cell of serine 5 phosphorylation would normally push for elongation but leads 
here to an increased degradation by NSs, since primarily elongating RPB1 is targeted for 
degradation. 
 
6.5. Mapping the functional domains of LACV NSs 
6.5.1. Functional domains in orthobunyavirus NSs 
Attempts to map the functional domains, for some of the reported NSs functions, have been 
made throughout the work for this thesis. The LACV NSs mutants I used were based on 
conserved sites throughout the orthobunyavirus genus (Fig. 10). Others have reported functional 
domains for SBV NSs in inducing RPB1 degradation [13] or determined amino acid residues 
important for BUNV NSs stability [157]. 
I have not directly looked at the stability of the mutants, but based on immunofluorescences 
analysis the mutants, except L11A, are more highly expressed than LACV NSs wt (Fig. 11). It 
is hard to draw a conclusion on the stability of the NSs mutants based on the Western blot 
results in Fig. 12C, since here the plasmids containing the NSs mutants are co-transfected with 
other plasmids that might compete for expression. The clearest result for the NSs mutants’ 
stability is seen in Fig. 11, since the plasmid was transfected alone in this experiment. The 
increased signal for all ectopically expressed LACV NSs mutants, except L11A, seemingly 
correlates with the lack of RPB1 degradation for these mutants. However we cannot exclude 
that the lack of lysine residues required for ubiquitinylation and proteasomal degradation, 
demonstrated for BUNV NSs [157], or a disturbed substrate recognition due to the alanine 
residues by the responsible E3 ligase, might play a role. 
For NSs of the related SBV, the functional domains required to induce RPB1 degradation was 
mapped to the C terminal part of the protein by ectopic expression of point of short deletion 
mutants [13]. The mutants in the C terminal part of SBV NSs did not induce RPB1 degradation, 
correlating with a loss of general host cell transcription inhibition from a CMV-promoter [13]. 
Contrary to these results, all my LACV NSs mutants still inhibit general transcription from the 
SV40-promoter (Fig. 12B). The difference between my results and the ones seen for SBV NSs 
might be the different promoter strengths for the reporters, the CMV-promoter is stronger than 
the SV40-promoter [176]. A second difference is the expression strength and stability of the 
respective NSs mutants. All my plasmid expressed mutants are detectable in non-induced 
samples (compare Fig. 12B & C), which best correlate with experiments performed for the SBV 
NSs mutants. The SBV NSs mutants were all barely detectable, and could only be visualized 
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after proteasomal inhibition [13]. This indicates that the LACV NSs, and mutants of it, are more 
stable than SBV NSs and its mutants. In addition the NSs-induced RPB1 degradation appears 
faster in LACV wt-infected cells (1 - 3 h.p.i., see Fig. 2) then in SBV wt-infected cells (6 – 15 
h.p.i. [13]). 
In our effort to map the functional domains of LACV NSs, we looked at several properties of 
the NSs protein; 1) the inhibition of general host cell transcription, 2) the inhibition of type I 
IFN induction, 3) the subcellular localization of the LACV NSs mutants and 4) the ability to re-
localize Elongin C. Via ectopic expression of the NSs mutants, the lack of Elongin C re-
localization by the NSs mutants correlated with their inability to inhibit type I IFN induction 
(compare Fig. 11 with Fig. 12A). The L11A mutant re-localized Elongin C and inhibited the 
type I IFN induction, indicating that this amino acid residue is not needed for these functions of 
the LACV NSs protein. The remaining N terminal mutants: 18to22A, 33to38A and 41to48A, 
had lost the ability to re-localize Elongin C and inhibit the type I IFN induction indicating that 
these residues in the NSs are important for both functions. The C terminal mutants: 57to59A, 
67to71A and 78to87A had all lost the ability to inhibit the type I IFN induction, but the ability 
of these mutants to re-localize Elongin C was inconclusive (Fig. 11 and Fig. 12A). The virally 
expressed LACV NSs mutants all retained the ability to induce the degradation of RPB1 to 
different degrees, but neither of them inhibited the transcriptionally active forms of RPB1 
(primarily CTDpSer 2) (Fig. 14B). All virally expressed mutants had lost the ability to inhibit 
the type I IFN induction, but still partially inhibited general transcription (Fig. 15), except 
78to87A. 
The current model for orthobunyavirus NSs inhibition of transcription is that all host cell 
transcription is down-regulated due to the inhibition/degradation of transcriptionally elongating 
RPB1 (CTDpSer 2). My results from the mutants screening demonstrated that I could dissect 
the transcription inhibition function since most of the LACV NSs mutants had lost the inhibition 
of type I IFN but still retained general cellular transcription inhibition. The inability to inhibit 
type I IFN induction by the ectopically expressed mutants correlated partially with the lack of 
Elongin C re-localization (compare Fig. 12A and Fig. 11). On the other hand, the lack of 
inhibiting type I IFN gene transcription by the virally expressed LACV NSs mutants correlated 
partially with the lack of inhibition of transcriptionally active RPB1 (Fig. 14A and B 
middle/lower and Fig. 15A and B). The inhibition of general cellular transcription did not reach 
NSs wt levels, except for ectopically expressed 33to38A and 41to48A, but was markedly 
decreased compared to Mock-treated or CTRL plasmid transfected samples (Fig. 12B and Fig. 
15C). A partial correlation between the ability to induce degradation of RPB1 and the inhibition 
of general host cell transcription was noted for the virally expressed mutants. However, the 
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observations made for the virally expressed NSs mutants need further experiments to be firmly 
established. 
6.5.2. Ectopic versus viral expression of the L11A mutant 
Two of the LACV NSs mutants, L11A and 78to87A, showed differences in loss-of-function 
depending on the expression system. The differences seen for the 78to87A mutant will be 
discussed in section 9.6. All the LACV mutants, except L11A, had lost the function of type I 
interferon inhibition, when both ectopically and virally expressed. However, the L11A mutant 
inhibited the type I IFN induction when ectopically expressed, but had lost the function when 
expressed by RVFV (Fig. 12A and Fig. 15A & B). This difference could not be explained by an 
increased sensitivity to the antiviral protein PKR, since the virus behaved similarly in PKR 
competent and knockdown cells (data not shown). RVFV is sensitive to the antiviral activity of 
PKR, which is relieved in infected cells by the proteasomal degradation of PKR induced by 
RVFV NSs wt [59]. A significant difference in protein levels could also not explain the 
difference between the ectopically and virally expressed L11A, since neither of the two can be 
detected in the respective experiment, but in RNA treated cells the ectopically expressed L11A 
inhibited type I IFN induction (Fig. 12A). A difference between the two experiments is the 
mode of type I IFN induction. In the transfection experiments a pulse of a fixed amount of 
inducer RNA was used. In the RVFV-infected cells there is a constant ongoing synthesis of new 
viral RNA, that amplifies the RIG-I pathway of the type I IFN induction [166]. Possibly, the 
L11A mutant is capable of inhibiting the induction due to a pulse of inducer RNA, while under 
conditions of ongoing viral replication, with a constant supply of RIG-I agonists, the LACV 
L11A mutant is not able to inhibit. This indicates that the NSs might be able to cope with small 
changes in its sequence for limited inductions of the type I interferon, but during the full-blown 
viral infection the NSs wt is needed for suppression. A similar requirement of the full-length 
RVFV NSs was reported, where short truncations throughout the NSs sequence resulted in a 
loss of anti-type I interferon activity [65]. 
 
6.6. LACV NSs interaction with Elongin C 
Elongin C is clearly re-localized from the nucleus by LACV NSs (see LACV wt infected 
samples in Fig. 5 and Fig. 7). Published Elongin C interactors, such as Elongin A and VHL, all 
contain a BC box [(STP)Lxxx(CSA)xxxɸ)] [93] that mediates the Elongin C interaction. By 
sequence alignment of the BC boxes from the VHL and Elongin A proteins and LACV NSs, a 
partial complementarity, between the BC boxes and the C terminus of LACV NSs was 
distinguished (Fig. 4). Interestingly, this region of the LACV NSs is very close to the region in 
the BUNV NSs that was determined to interact with MED8 [89]. Importantly, the partial LACV 
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NSs BC box contains the conserved leucine residue that has been determined to be crucial for 
Elongin C interaction [145]. Even though the conserved leucine residue is present at the correct 
position, the two other positions in the BC box (amino acid residue 1 and 6) are not conserved 
in LACV NSs. However, a few of the residues have the same biochemical properties as those 
seen in the VHL and Elongin A BC boxes. In addition, the small size of the LACV NSs might 
adopt an induced fit structure upon binding to Elongin C that could compensate for the lack of 
the important residues. An induced fit model would also explain why most of the NSs protein, 
the C terminal ~70 amino acid residues, is needed for interaction (Fig. 11). All of the mutants 
still contain the important leucine residue, and only in the 78to87A mutant are parts of the 
potential BC box missing. Unfortunately, no clear phenotype for the Elongin C re-localization 
was obtained for this mutant when ectopically expressed (Fig. 12). However, this mutant was 
the only one to have lost both the inhibition of general host cell transcription and type I IFN 
induction, when virally expressed (Fig. 15A, B and C). It would be of interest in the future to 
create an alanine mutant of LACV NSs, lacking the BC box motif, and study its phenotype. 
 
6.6.1. Significance of LACV NSs induced Elongin C re-localization 
LACV NSs interaction with Elongin C is seen in immunofluorescence as the disappearance of 
the signal for Elongin C (Fig. 5). The interaction between NSs and Elongin C does not cause a 
visible re-localization of Elongin C, as can be seen for e.g. Cullin 5 in adenovirus infected cells 
where Cullin 5 is re-localized to the nucleus by the interaction with adenovirus E4orf6 protein 
[118], or during DNA damage where Elongin A and Cullin 5 co-localize at sites of DNA-
damage [79, 174]. The reason for the disappearance of the Elongin C signal might be due to a 
dilution effect by the CRM1 dependent re-localization to the cytoplasm (Fig. 8). In the nucleus, 
Elongin C is concentrated to the nucleoli and easy to detect while no such effect is seen in the 
cytoplasm were it would be evenly distributed. A second possible reason for the disappearance 
of the Elongin C signal might be that LACV NSs binds Elongin C at the same position, or 
nearby, as the antibody. Steric hindrance of antibody binding to the Elongin C protein would 
then cause a lack of signal in immunofluorescence. Unfortunately the manufacturer does not 
state to which epitope, on the Elongin C protein, the monoclonal antibody was raised. Elongin C 
is only 14 kDa in size so the whole protein might have been used for immunization. 
A surprising observation is that LACV NSs has no effect on Elongin B localization (lower part 
of Fig. 6), when most studies on Elongin B/C have reported that this sub-complex is needed for 
activity. Elongin B/C forms a stable complex and when one of the two is lacking the other is 
also destabilized (Fig. 16A). However, during infection by LACV wt, no obvious 
destabilization of Elongin B was noted (Fig. 5 and Fig. 6 lower). The lack of a destabilization 
during infection by LACV wt might be because not all Elongin C proteins are re-localized by 
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the NSs protein, leaving sufficient amounts of Elongin C to interact with Elongin B. For the 
Elongin C function, in increasing transcription elongation rates, the interaction with Elongin A 
was studied in vitro, and the subcellular localization of the Elongin complex has never been 
reported. Similarly, studies on the formation of E3 ubiquitin ligases, both cellular and viral, 
have been performed in vitro. Only the sub-cellular localization of Cullin 5 and/or Elongin A 
has been reported to change upon e.g. DNA damage [168] of infection with Adenoviruses [118]. 
The interaction between NSs and Elongin C might disrupt the Elongin C/Elongin B interaction. 
I tried, in pull down experiments, if I could out-compete Elongin B from Elongin C by adding 
increasing amounts of the LACV NSs wt protein. Unfortunately, the basic pull down procedure, 
to detect interaction between LACV NSs and Elongin C, could never be robustly established 
(see section 8.2 in the Results), therefore the possible disruption of Elongin B/Elongin C 
interaction, by LACV NSs, could not be studied.  
 
6.6.2. Functional significance of Elongin C re-localization 
Based on the published functions of Elongin C, the re-localization by LACV NSs might work 
via one of two different mechanisms. The first mechanism would be that Elongin C re-
localization causes a decrease in RNAPII transcription elongation rates and an increased stalling 
frequency of RNAPII. RPB1 degradation would then be an indirect effect promoted by an as yet 
unknown E3 ligase. The second mechanism would be that LACV NSs induces the formation of 
a ubiquitin E3 ligase, containing Elongin C, which directly targets RPB1 for degradation. 
The first mechanism, where LACV NSs re-localization of Elongin C leads to an increased 
stalling of RNAPII, would lead to an indirect degradation of RPB1. Elongin C potentiates the 
function of Elongin A, which interacts with RNAPII and increases the transcription elongation 
rates [9]. A sequestration of Elongin C by the NSs would probably cause a decrease in Elongin 
complex promoted transcription. Yet, published Elongin complex dependent transcription is so 
far restricted to neuronal developmental [175] and stress response genes [79], and has not been 
implicated in general or innate immune gene transcription. In the LMB experiment we could 
rescue the nuclear, and partially the nucleolar localization of Elongin C, but RPB1 was still 
degraded (Fig. 8 and Fig. 9). This demonstrates that RPB1 degradation takes place directly in 
the nucleus, and that sequestration of Elongin C by the LACV NSs might be the important step. 
The disappearance of the Elongin C signal during LACV wt infection might just be a phenotype 
of the interaction and not the mechanism. Even though Elongin C is retained in the nucleus in 
LMB treated cells, the LACV NSs interaction with Elongin C might sterically hinder Elongin 
A/Elongin C interaction and thereby cause a stalling of RNAPII. 
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The second mechanism is that LACV NSs forms a ubiquitin E3 ligase containing Elongin C, 
which could directly target RPB1 for proteasomal degradation. However, in an effort to 
determine components of the LACV NSs E3-ligase responsible for RPB1 degradation, 
knockdowns of Cullin 2 and/or Cullin 5 were performed. Both these Cullins have been 
demonstrated to be part of several E3 ligases also containing Elongin B/C [80, 93, 111]. 
Unfortunately, all cells tested had very low to undetectable levels of both Cullins. We were 
unable to detect even basic levels of either Cullin mRNA or protein via RT real-time PCR or 
Western blot, respectively, in control treated samples (data not shown). Furthermore, LACV wt 
infection of Cullin 2 and/or 5 knockdown cells did not result in a rescue of RPB1 from 
degradation (data not shown). The lack of an effect might be due to the low basic levels of 
Cullin 2/5 mRNA that is unaffected by siRNA directed degradation. It might also be that the 
low level of Cullin 2 or 5 mRNA still provides enough translated protein and/or that that these 
proteins are very stable. However, the lack of detection of basic levels of the two Cullins and 
the LACV NSs induced RPB1 degradation in all mammalian cell types tested indicate that 
ubiquitously expressed proteins are involved in the degradation. In addition, no Cullin box that 
is found in Cullin 2 or 5 interacting proteins [78], could be detected in LACV NSs. A protein 
forming an E3 ligase complex with Elongin B/C, contains a Cullin box downstream of the BC 
box, which mediates both the interaction and selection for which of the two Cullins, Cullin 2 or 
5, that is recruited to the E3 ligase. No such sequence was found in LACV NSs making it 
unlikely that it forms a conventional E3 ligase. In parallel to my attempts to rescue RPB1 from 
degradation by knocking down Cullin 2/5, attempts to rescue p62 (a subunit of the general 
transcription factor THIIH) from degradation induced by RVFV NSs, the knockdown of Cullin 
1 and/or 7 did not have any effect on the degradation [75]. Cullin 1/7 is recruited to E3 ligases 
by Skp1, which as already mentioned, share both amino acid sequence and function with 
Elongin C in ubiquitin E3 ligase formation. 
Neither of these two models fully explains nor fits with the majority of the results. A 
mechanism where LACV NSs forms a ubiquitin E3 ligase that directly targets RPB1 for 
proteasomal degradation, would fit with the rapid induction of degradation (1 – 3 h.p.i.), the re-
localization (formation of the E3-ligase) and the partial rescue of both RPB1 and type I IFN 
induction in Elongin C knockdown cells. However, the rescue in Elongin C knockdown cells is 
only partial and does not reach levels of RPB1 seen in Mock or LACV ΔNSs infected cells, 
indicating that other mechanism(s) of LACV NSs plays a role in RPB1 degradation induction. 
Another protein that might also play a role in LACV NSs induced RPB1 degradation is 
NEDD4, the initial E3 ligase responsible for mono-ubiquitinylating RPB1 during the DNA 
damage response (Ref), see section 4.7.3. of the introduction. Work in our group has 
demonstrated that siRNA mediated knockdown of NEDD4 partially rescues both RPB1 from 
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degradation and induction of type I IFN. Furthermore, ectopic expression of ubiquitinylation-
competent NEDD4 re-localized to the perinuclear region in LACV wt infected cells, while this 
was not seen during LACV ΔNSs infection or for ubiquitinylation-deficient NEDD4 
(Spiegelberg, L. & Weber, F., unpublished). I have performed single or double knockdown of 
Elongin C and/or NEDD4 in HeLa cells. However, I did not observe any additional rescue of 
RPB1 from degradation or induction of type I IFN, when comparing the single and double 
knockdowns. The lack of additive effect in the double knockdown might be due to the HeLa 
cells used. NEDD4 showed the most pronounced knockdown efficiency in these cells while 
Elongin C knockdown was not as efficient as in A549 cells. Unfortunately, an efficient double 
knockdown could not be established for the same cell line. 
 
6.7. Final Conclusions 
The experiments performed and presented in the thesis have been aimed at clarifying the role of 
the LACV NSs interaction with Elongin C, and the function this interaction fulfils during 
infection. LACV NSs clearly re-localizes Elongin C from the nucleoli (Fig. 5 and Fig. 7), but 
the exact role of the re-localization, to induce RNAPII stalling and RPB1 degradation or 
formation of an E3 ligase that directly targets RPB1 for proteasomal degradation, could not be 
established. 
With our loss-of-function alanine mutants of LACV NSs, we have established the previously 
unknown separation of inhibition of type I IFN induction and RPB1 degradation. All LACV 
NSs mutants had lost the ability to inhibit type I IFN, except L11A expressed from plasmid, 
while all LACV NSs mutants still inhibited general transcription, except LACV NSs 78to87A 
expressed by RVFV. The inhibition of general transcription by the RVFV expressed mutants 
partially correlated with the ability to induce degradation of RPB1. Furthermore, the loss of type 
I IFN inhibition correlated with the loss of Elongin C re-localization by the ectopically 
expressed LACV NSs mutants, and/or the inability to inhibit transcription elongating RPB1 for 
the virally expressed LACV NSs mutants. The separation of the inhibition of the type I IFN 
induction and RPB1 degradation indicates that LACV NSs might have two separate inhibitory 
functions on host cell transcription. General transcription inhibition is induced by degrading 
RPB1 while inhibition of type I IFN induction works via a different mechanism, possibly re-
localization of Elongin C and/or decreased transcriptionally active RPB1 (mainly CTDpSer 2). 
The dissection of these two transcription inhibition mechanisms will further both the knowledge 
of the orthobunyavirus NSs function and mammalian RNAPII transcription. 
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The work presented here further establishes the critical role of LACV NSs as a model for all 
orthobunyavirus NSs proteins in inhibiting the type I IFN induction by inducing the degradation 
of transcriptionally elongating RPB1, to promote orthobunyavirus infection of mammalian cells. 
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8. Appendices 
Appendix 1 – Full orthobunyavirus NSs alignment 
 
 
 
 
 
 
 
 
 
 
Alanine mutants A
L11A
AAAAA
18to22A
AAAAAA
33to38A
AAAAAAAA
41to48A
AAA
57to59A
AAAAA
67to71A
AAAAAAAAAA
78to87A
Conserved domains *
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